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Cardiac malformations (CVMs) are a leading cause of infant morbidity and 
mortality. CVMs are particularly prevalent when the developing fetus is exposed 
to high levels of phenylalanine in-utero in mothers with Phenylketonuria. Yet, 
elucidating the underlying molecular mechanism leading to CVMs has proven 
difficult. In this study we used RNA-Seq to investigate an avian model of MPKU 
and establish differential gene expression (DEG) characteristics of the early 
developmental stages HH10, 12, and 14.  In total, we identified 633 significantly 
differentially expressed genes across stages HH10, 12, and 14. As expected, 
functional annotation of significant DEGs identified associations seen in clinical 
phenotypes of MPKU including CVMs, congenital heart defects, craniofacial 
anomalies, central nervous system defects, and growth anomalies. Additionally, 
there was an overrepresentation of genes involved in cardiac muscle contraction, 
adrenergic signaling in cardiomyocytes, migration, proliferation, metabolism, and 
cell survival.  Strikingly, we identified significant changes in expression with 
multiple genes involved in Retinoic Acid (RA) metabolism and downstream 
targets. Using qRTPCR, we validated these findings and identified a total of 42 
genes within the RA pathway that are differentially expressed. Here, we report the 
first elucidation of the molecular mechanisms of cardiovascular malformations in 
MPKU conducted at early developmental timepoints. We provide evidence 





suggesting a link between PHE exposure and the alteration of RA pathway. These 
results are promising for potential targeted therapeutic interventions in 
individuals with MPKU.  Additionally, we introduce genes of interest that were 
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Chapter 1:  Introduction 
Phenylketonuria 
 Phenylketonuria (PKU) is an autosomal recessive disorder that affects 1 in 
15,000 Caucasian newborns and there is lesser or greater incidence in other 
populations of newborns [1].  Patients with PKU are deficient in the liver enzyme, 
Phenylalanine Hydroxylase (PAH), causing a reduced or absent metabolism of 
Phenylalanine (PHE) to Tyrosine leading to a toxic serum level of PHE [2].  PHE 
is an essential amino acid obtained from diet and the deficiency in PAH leads to 
an inability to control levels of PHE, therefore it builds up to toxic levels.  High 
levels of PHE and its metabolites cause severe intellectual disability and 
neurological conditions.  Currently, newborn babies are routinely screened and 
identified at birth.  However,  the implementation of newborn PKU screening was 
not uniformly introduced  across all states or worldwide and in these cases women 
are unaware of having PKU until later in life [3].   Currently newborns are 
consistently tested at birth in the US and in cases of known PKU, strict monitoring 
of the levels of PHE and adherence to diet has allowed individuals to live relatively 
normal lives with no cognitive impairment.  This early identification of PKU has 
led to the most successful treatment [4].  Currently, the only effective treatment for 




restricted diet is possible it is not easy and long-term adherence is less successful.  
Many women are going off diet leading to increased levels of PHE and an 
increased risk of Maternal Phenylketonuria (MPKU) in offspring/children. 
Maternal Phenylketonuria and Cardiac Malformations 
 When a female with PKU is pregnant, her fetus will be negatively affected by 
intrauterine exposure of increased levels of PHE, this disease is known as MPKU.  
In cases of MPKU, offspring have exhibited cardiovascular malformations (CVMs) 
[5].  Additionally, offspring exhibit microcephaly, facial abnormalities, growth 
restriction, and mental retardation [6].  Currently among all births, CVMs are a 
leading cause of infant mortality, occurring at a rate of 5-8/1000 live births [7, 8]. 
CVMs are caused by genetic and environmental exposure such as MPKU, ethanol 
exposure, and maternal diabetes [9, 10].  Early identification and diet restriction 
has led to increased numbers of women diagnosed with PKU reaching 
childbearing age and the need for further investigation of MPKU is of increasing 
importance.  Currently, treatment of MPKU is limited and not ideal.  The 
extremely restricted diet low in PHE is difficult to maintain and it is reported that 
observance reduces with time [11]. More importantly in cases of MPKU, adherence 
to a strict diet gives the highest probability of healthy offspring.  Often, women 





with PKU have unintended pregnancies and may not be in compliance with PHE 
levels at the time of conception or even within early development of the embryo 
[3].  Additionally, women with PKU who discontinue diet at an early age 5-6 years, 
do not remember why they were on the diet or what disease they have [3].  Initial 
reports noted CVMs were observed in 7-15% of pregnancies of PKU mothers on 
uncontrolled diet [3]. The more extensive MPKU study of 412 PKU pregnancies 
demonstrated 14% of the offspring were born with a CVM. The most commonly 
occurring CVMs observed are Coarctation of the Aorta (CoA), Tetralogy of Fallot 
(TOF), Ventricular Septal Defect (VSD), Patent Ductus Arteriosus (PDA), Atrial 
Septal Defect (ASD), Persistent Truncus Arteriosus (PTA) and Hypoplastic Left 
Heart Syndrome (HLHS) [2, 12]. 
Interestingly, the molecular mechanisms of teratogenicity in the presence 
of PHE are not known.  To date, the effects of PHE exposure on gene expression 
in the developing heart has not been investigated.  RNA-Sequencing (RNA-Seq), 
a molecular technique used to identify gene expression, was used to compare 
vehicle control injected embryos to PHE injected animals to elucidate novel 
changes in gene expression that may be associated with the development of CVMs. 





Chick Model in Heart Development 
Historically chick embryos have been used to study patterning of early 
development such as axes, germ layers,  and organogenesis [13].  The chicken is 
used in embryology and developmental studies because of ex utero development 
with availability and affordability.  The chick embryo is easily manipulated and 
observed in many types of experiments notably, grafting, microinjection, and 
lineage tracing [14-16].  Most importantly, chick is the only other non-mammalian 
organism whose heart anatomy most resembles humans with four chambers and 
in- and out-flow tracts [17].  The chicken embryo developmental stages were 
extensively studied and documented by Hamburger and Hamilton (HH) and 
allow for easier staging and experimentation at specific stages in heart 
development [18, 19].  At HH10-14, the heart is still developing and remodeling 
(Figure 1) [20].  Primary and secondary heart field cells populate the heart first.  
Then, the cardiac neural crest cells (cNCC) begin to ingress from the neural tube 
through the pharyngeal arteries continuing into the heart.  The cell population of 
cNCCs is necessary for remodeling of the aortic arch and the septation of the 
outflow tract into the pulmonary artery [21].  Additionally at HH14, the chambers 
of the heart are undergoing remodeling and atria/ventricle septation to ensure 
proper function and blood flow [22]. 






Figure 1.  Chick Heart Development. 
Chicken heart development from HH stages 10, 12, and 14. 
 
Retinoic Acid Signaling in Heart Development 
Vitamin A/retinol metabolized inside the cell through a series of enzymatic 
reactions and transport with serum proteins, cellular receptors, and nuclear 
receptors.   Vitamin A and Carotenoids, that later become retinoic acid (RA), are 
sourced only through the diet.  Vitamin A is acquired in the diet from milk, eggs, 
and liver.  Carotenoids are found in plants such as carrots and sweet potato.  In 
humans, retinoids are received from the mother across the placenta in the form of 
retinol or β-carotene.  In chicken, the retinoids are maternally deposited in the yolk 
[23]. 
For cell signaling, hydrophobic Vitamin A is transported as retinol by 
Retinol Binding Protein 4 (RBP4) [24] and Transthyretin (TTR) complex to cell 





surface receptors such as Stimulated by Retinoic Acid 6 (STRA6) or predominately 
through diffusion across the cell membrane (Figure 2) [25].  STRA6 takes the 
metabolite into the cell and it is delivered to Cellular Retinol Binding Protein 
1(CRBP1, RBP1) [26, 27].  The metabolite is then further modified to retinaldehyde 
by Retinol Dehydrogenase 10 (RDH10) and to its active signaling molecule RA by 
Retinaldehyde Dehydrogenase 2 (RALDH2).  RALDH2 is also known as Aldehyde 
Dehydrogenase 1 family member A2 (ALDH1A2).   RA is then able to act as a 
transcription factor by entering the nucleus through nuclear receptor Cellular 
Retinoic Acid Binding Protein 2 (CRABP2), inducing developmental gene 
expression or repression [25]. Cellular Retinoic Acid Binding Protein 1 (CRABP1) 
may sequester or shuttle RA to the Cytochrome P450 Family 26 (CYP26), family of 
enzymes where it can undergo catabolism and be eliminated to maintain the 
suitable levels of RA [28].  Mutations in the CYP26 enzymes create a 
microenvironment resembling surplus RA in mouse models [29]. 
The ADH family of to cytosolic alcohol dehydrogenases are able to oxidize 
retinol to retinal and produce RA in vivo during embryogenesis [23].  
Retinaldehyde Dehydrogenase 2 (RALDH2) is responsible for the majority of 
retinaldehyde to RA during embryo development and has been shown in 
RALDH2-/- mice to be necessary for survival [30].  In addition to gene expression 





RA can act through paracrine signaling on neighboring cells.  RA may diffuse and 
act as a morphogen on other cells [31]. 
RA signaling is involved in multiple embryonic developmental processes.  
RA signaling is highly regulated through development as too much, too little, or 
abnormal distribution negatively affects development.  Too little Vitamin A is 
known as Vitamin A Deficiency (VAD) which causes abnormalities in the 
development of many organs including heart [32, 33].   Improper RA signaling has 
previously been shown to affect cardiogenesis in avian embryos, decreasing the 
expression of GATA Binding Protein 4 (GATA-4), a heart transcription factor.  This 
was rescued with dietary supplementation of Vitamin A [34].  Excess Vitamin A 
or RA causes malformations in heart and other organs [35].  VAD can be rescued 
with Vitamin A or RA supplementation preventing developmental defects.  
Conversely,  in cases of too much RA, RA acts as a teratogen  causing 
developmental defects [23].  Correct signaling is achieved through multiple 
proteins functioning in Vitamin A metabolism, transport, nuclear signaling, and 
RA catabolism[23]. 
 It has previously been shown that phenylalanine (PHE) effects heart 
development [5-8], therefore the hypothesis is chick embryos exposed to high PHE 
will develop heart defects in the aortic arch arteries (AAA) and the outflow tract 





(OFT) resultant from alterations in gene expression in cardiac and surrounding 
tissues.  Investigating this hypothesis will improve our understanding of how 
exposure to teratogens affects heart development and potentially uncover novel 
pathways in heart development.    Additionally, the objective is to determine 
differentially-expressed genes in the heart and thoracic region in the presence of 
PHE and find potential mechanisms of CVMs in MPKU.  The rationale is that while 
it is known that PHE affects embryonic heart development, it has not been shown 
which genes are differentially expressed (DE) in the microenvironment of PHE.   
The new knowledge gained from this research will contribute to the development 
of new diagnostics and treatments ultimately reducing the morbidity, mortality, 
and cost associated with CVMs.  Furthermore, elucidating a mechanism for the 
development of CVMs will allow for potential therapeutic interventions for 
individuals with MPKU. 
 To test our hypothesis, first differentially expressed genes (DEGs) were 
determined using RNA sequencing. Genes of interest identified through RNA 
sequencing and with significance in heart development were further investigated 
through Quantitative Real Time Polymerase Chain Reaction (qRTPCR) and in situ 
hybridization.  Through this work we present novel investigations into the 
molecular effects of PHE on heart development in chicken.  Additionally, we 











Figure 2.  Retinoic Acid metabolism from Stefanovic etal.





Chapter 2:  RNA-Seq Analysis in an Avian Model of Maternal Phenylketonuria 
Introduction 
Phenylketonuria 
Phenylketonuria (PKU; OMIM #261600) is an autosomal recessive disorder of 
Phenylalanine (PHE) processing [36] with 1 in 10,000 newborns affected [1, 37]. 
The development of a rapid and inexpensive test for PKU in the 1960s resulted in 
early identification of affected newborns that is still done as part of routine 
screening at birth in the US [38, 39]. Currently, the standard treatment is a PHE- 
restricted diet; therefore, strict dietary adherence has allowed affected individuals 
to live relatively normal lives free from explicit symptoms [40]. 
Yet, the PKU dietary regimen is onerous and compliance is complex due to 
issues including convenience, cost, and availability of dietary options. As a result, 
adherence is inconsistent across the lifespan [41]. One unintended consequence 
of poor dietary adherence occurs in females of reproductive age in which their 
uncontrolled levels of PHE result in congenital anomalies in over 90% of children 
(termed “Maternal Phenylketonuria” (MPKU) [5, 42]. PHE crosses the placenta 
into the fetal compartment creating an adverse developmental condition in which 





fetal blood levels are 1.5 to 2.0-fold higher than maternal levels[43]. This creates a 
direct dose-response relationship between maternal blood PHE and birth defect 
incidence [44, 45]. MPKU clinical phenotypes include stunted growth, facial 
dysmorphologies, cognitive impairment, and cardiovascular malformations 
(CVMs) [5, 43, 46-48]. 
Maternal Phenylketonuria and Congenital Malformations 
One of the most severe MPKU associated congenital anomalies, CVMs, are a 
leading cause of infant mortality and occur in up to 15% of MPKU live-born 
children [5, 7, 8, 42, 49]. The most commonly occurring CVMs observed are 
Coarctation of the Aorta (CoA), Tetralogy of Fallot (TOF), Ventricular Septal 
Defect (VSD), Patent Ductus Arteriosus (PDA), Atrial Septal Defect (ASD), 
Persistent Truncus Arteriosus (PTA) and Hypoplastic Left Heart Syndrome 
(HLHS) [1-3]. 
To date, animal models of MPKU associated CVM development have yet to 
illuminate the molecular mechanisms of teratogenicity and CVM pathogenesis 
[46-48]. Molecular studies have been limited to late-stage mouse embryos that 
focus on the resultant alterations in gene expression after CVM occurrence [44]. 
Thus, in order to robustly elucidate the molecular changes that lead to the 





development of CVMs, there is a clear need for an early model of gene expression 
changes in MPKU. 
The purpose of this study is to investigate the etiology of CVMs by 
investigating global gene expression levels during early cardiac development. To 
our knowledge this is the first investigation elucidating a global picture of gene 
expression changes that may cause CVMs in the presence of PHE. Our significant 
results will allow for individually tailored preventive measures and targeted 
therapies. 
Materials and Methods 
Ethics Statement 
All animal procedures were carried out in accordance with the U.S. Public 
Health Service Policy on Humane Care and Use of Laboratory Animals and the 
Animal Welfare Act.  All protocols were performed with the approval of the 
Institutional Animal Care and Use Committee (IACUC) at University of Central 
Oklahoma. 





Injections and Incubation Conditions 
Fertilized white leghorn chicken eggs were purchased from Texas A&M 
Poultry Sciences. Eggs were incubated at 37.2˚C and 50% humidity until 
Hamburger and Hamilton (HH) stage 6 [18]. Eggs were removed from the 
incubator and the shell of the eggs was sterilized using a 70% ethanol. Using a 16-
gauge needle, a small hole was drilled through the air pocket. A 27-gauge needle 
was inserted into the hole and eggs were treated with 200µl of either 2.5mM PHE 
or vehicle control (1 x PBS) through the blunt end of the egg as described 
previously (yolk injection) [50]. After yolk injection the hole in the shell was 
sealed with tape and the embryos were further incubated until HH 10, 12 or 14. 
We selected HH 10, 12, and 14 due the critical changes occurring in heart at these 
early development stages (these changes include cardiac neural crest cells (cNCC) 
ingression from the neural tube into the pharyngeal arteries for remodeling of the 
aortic arch and the outflow tract [21] and atrial/ventricular septation to ensure 
proper function and blood flow [19, 22].  At HH 10, 12, or 14 the embryos were 
collected by dissection. The thoracic/cardiac region between the otic placode and 
the 3rd somite were dissected and used for RNA isolation. For HH stages 10 and 
12, a total of 3 PHE treated embryos and 3 control embryos were used. 





Experiments were repeated as described above. For HH 14, tissues from 3 control 
embryos were pooled. A total of 2 PHE treated samples were isolated for RNA 
collection. 
RNA Isolation, Library Preparation, & Illumina Sequencing 
Total RNA was isolated using the PicoPure™ RNA Isolation Kit (Thermo 
Fisher Scientific, Waltham, MA, USA, KIT0204), according to manufacturer’s 
protocol followed by storage at -80˚C. The quality and quantity were analyzed 
using a Nanodrop spectrophotometer (Thermo Fisher Scientific) and a total of 2.5 
µg high quality RNA (RIN> 8.0) [51] was shipped to Applied Biological Materials 
Inc (ABM; Richmond, BC, Canada). Additional rigorous RNA quality analyses 
were performed by AMB (Aligent 2100 Bioanalyzer) and after the samples passed 
the quality verification, they were processed for library preparation and 
transcriptome sequencing. Subsequently, the RNA was enriched for Poly-A 
selection followed by fragmentation, first and second strand synthesis, 
adenylation of 3’ ends, adaptor ligation, DNA fragment enrichment, and real-
time PCR quantification. Samples were then sequenced using Next Generation 
Sequencing (NGS) on the Illumina NextSeq 500 at ABM. 






The quality of the sequencing reads was determined using the Fast QC [52] 
program, length of fragments, and number of sequence reads (Supplemental 
Figures 3-8). The average size of the sequence reads were 300bp, indicating a 
homogenous library construction. All to the sequence reads for the samples were 
greater than 10 million, representing thorough coverage of the genome. Bases 
were trimmed for HH 10 and 12 samples (9 bases) (Supplemental Figure 1) and 
for HH 14 samples (6 bases) (Supplemental Figure 2). Raw FASTQ data were 
received and analyzed using open source software, Galaxy Suite from Penn State 
University (https://usegalaxy.org/). A workflow of sample processing is shown in 
Supplemental Figure 11.  The RNA-Seq reads were first aligned to Gallus gallus 
genome (galGal4) using and Tophat/Hisat [53, 54]. We compared PHE treated to 
vehicle control (PBS) embryos to determine differential gene expression using 
CuffDiff [55]. Differential Gene Expression statistical analysis was conducted in 
Galaxy Suite. A-priori statistical significance was set (q-value ≤0.05, p-value ≤ 
0.05) and all significant gene name symbols were retained for further analysis. 





Gene Ontology & Statistical Analysis 
To identify high-level biological functions and interactions, significant 
gene name symbols were uploaded through The Database for Annotation, 
Visualization and Integrated Discovery (DAVID; vs. 6.8) and then analyzed with 
Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, enriched 
Gene Ontology (GO) Terms, and Genetic Association Database (GAD) [56, 57]. 
All analyses were conducted with program defined defaults. The p-value was 
calculated using a modified Fisher Exact Test that, for a given annotation process, 
is calculated by considering both the number of focus genes within that process 
and the total number of genes that are associated with that process in the 
reference set [47]. It is noted that Fisher’s Exact Test can be overly conservative 
with small sample sizes [48, 49]. For specific hypothesis testing, we used the 
Benjamini-Hochberg method of correction for multiple testing [46, 47]. 
Validation of Results 
Selected genes were further validated at embryonic HH 14 through 
Quantitative Real Time PCR (qRTPCR). RNA was prepared for embryos as 
previously described (2.3). Then, the cDNA library was prepared by reverse 
transcribing 2µg of RNA using High-Capacity cDNA Reverse Transcription Kit 





(Fisher Scientific, Hampton, NH, USA, 4368814) with SyberGreen Maxima 
Mastermix (Thermo Fisher Scientific, K0221) per the manufacturer’s protocols. 
The reaction was carried out on iCycler™ Optical Module Thermocycler (Bio-
Rad, Hercules, CA, USA). Validation genes were selected based upon significance 
in cardiac relevant biological pathways and statistical significance.  Additionally, 
commercially available custom Retinoic Acid Pathway qRTPCR plates in Gallus 
gallus were purchased (Qiagen, Hilden, Germany). Based on previous qRTPCR 
work in this model, all genes were normalized to the housekeeping gene 
RPL4[58]. 
Results 
Differentially Expressed Genes & Functional Annotation 
We identified 110 (HH10) (5.37X10-3 to 4.92X10-2 q-value, -4.52 to 6.11 fold 
change), 412 (HH12) (2.16X10-3 to 4.99X10-2 q-value, -5.26 to 2.48 fold change), and 
111 (HH14) (5.00X10-5 to 5.00X10-2 p-value, -1.95 to 5.27 fold change) differentially 
expressed genes (total = 633) between PHE treated and vehicle-control embryos.  
We identified 41 upregulated genes (37.27%) and 69 downregulated (62.73%) 
(HH10), 191 upregulated genes (46.36%) and 221 downregulated (53.64%) 
(HH12), and 44 upregulated genes (39.64%) and 67 downregulated (60.36%) 





(HH14) between PHE treated and vehicle-control embryos.  After filtering by 
>±1.5-fold change, we identified 31 (HH10), 43 (HH12), and 8 (HH14) 
differentially expressed genes (total = 82) between PHE treated and vehicle-
control embryos (Table 1).  Values ranged from -5.26 to +5.27 fold-change, and p-
value 5.00X10-5 to 4.55X10-2. Next, we examined the association of these genes 
with known disease phenotypes of MPKU using GAD. We identified associations 
with CVMs or congenital heart defects (genes = 13), craniofacial anomalies (genes 
= 8), central nervous system defects (CNSD) (genes = 13), and growth anomalies 
(genes = 10) for a total of 30 (42.3%) out of the 71 different significant DEGs. 
Additionally, 9/71 (12.7%) were associated with two or more MPKU phenotypes 
(Table 1). 
Differential Gene Expression GAD Analysis-MPKU Phenotype 
HH 
Stage  




p-value q-value Cardiac Craniofacial CNS Growth 
10 NR2E1 
nuclear receptor subfamily 
2 group E member 1 4.44 5.00E-05 5.37E-03 
    +   
10 AKR1BL 
aldo-keto reductase family 
1 member B1-like 3.97 5.00E-05 5.37E-03 
        
10 RAX 
retina and anterior neural 
fold homeobox 3.90 5.00E-05 5.37E-03 
  + +   
10 NKX2-1 NK2 homeobox 1 3.83 5.00E-05 5.37E-03     +   
10 OLIG3 
oligodendrocyte 
transcription factor 3 3.46 5.00E-05 5.37E-03 
      + 
10 DBX1 
developing brain 
homeobox 1 3.22 5.00E-05 5.37E-03 
      + 
10 SLCO4A1 
solute carrier organic 
anion transporter family 
member 4A1 2.99 5.00E-05 5.37E-03 
        
10 OTX2 orthodenticle homeobox 2 2.63 5.00E-05 5.37E-03   + +   
10 OCX36 
BPI fold containing family 
B member 3 2.54 5.00E-05 5.37E-03 
        








sialyltransferase 2 1.85 5.00E-05 5.37E-03 
    +   
10 PAX6 paired box 6 1.77 5.00E-05 5.37E-03   + + + 
10 APC2 
adenomatosis polyposis 
coli 2 1.60 5.00E-05 5.37E-03 
        




family) -1.67 5.00E-05 5.37E-03 
        
10 APOC3 apolipoprotein C3 -1.67 5.00E-05 5.37E-03         
10 APOA1 apolipoprotein A-I -1.75 5.00E-05 5.37E-03         
10 MT4 metallothionein 4 -1.75 5.00E-05 5.37E-03         
10 CRABP1 
cellular retinoic acid 
binding protein 1 -1.75 5.00E-05 5.37E-03 
  +     
10 FGA fibrinogen alpha chain -1.88 5.00E-05 5.37E-03         
10 TNNC2 troponin C type 2 (fast) -1.91 5.00E-05 5.37E-03 +       
10 MYL2 
myosin, light chain 2, 
regulatory, cardiac, slow -2.04 5.00E-05 5.37E-03 
+       
10 MYL3 
myosin, light chain 3, 
alkali; ventricular, skeletal, 
slow -2.27 5.00E-05 5.37E-03 
+       
10 SEPP1 selenoprotein P1 -2.32 5.00E-05 5.37E-03         
10 PTGDS 
prostaglandin D2 synthase 
21kDa (brain) -2.53 5.00E-05 5.37E-03 
        
10 ALDOB 
aldolase B, fructose-
bisphosphate -2.86 5.00E-05 5.37E-03 
        
10 APOB apolipoprotein B -2.97 5.00E-05 5.37E-03 +       
10 RBP riboflavin binding protein -3.12 5.00E-05 5.37E-03         
10 FBP1 
fructose-1,6-
bisphosphatase 1 -3.59 5.00E-05 5.37E-03 
  +     
10 TGM4 
transglutaminase 4 
(prostate) -3.62 5.00E-05 5.37E-03 
      + 
10 HBE 
hemoglobin subunit 
epsilon -4.33 5.00E-05 5.37E-03 
        
10 HBG1 
hemoglobin beta, subunit 
rho -4.52 5.00E-05 5.37E-03 
        
12 HBG2 hemoglobin, beta 2.48 5.00E-05 2.16E-03         
12 HBG1 hemoglobin, beta 2.33 5.00E-05 2.16E-03         
12 HBE 
hemoglobin subunit 
epsilon 2.33 5.00E-05 2.16E-03 
        
12 PLN phospholamban 1.83 5.00E-05 2.16E-03 +       
12 IFI27L2 
interferon, alpha-inducible 
protein 27-like 2 1.81 5.00E-05 2.16E-03 
        
12 MB myoglobin 1.78 5.00E-05 2.16E-03 +   + + 
12 SERPINI1 
serpin peptidase inhibitor, 
clade I (neuroserpin), 
member 1 1.75 5.00E-05 2.16E-03 
        
12 TNNC2 troponin C type 2 (fast) 1.74 5.00E-05 2.16E-03 +       






solute carrier family 4, 
anion exchanger, member 
1 1.70 5.00E-05 2.16E-03 
        
12 MYL2 
myosin, light chain 2, 
regulatory, cardiac, slow 1.69 5.00E-05 2.16E-03 





activating polypeptide 1 
(pituitary) 1.60 5.00E-05 2.16E-03 
    +   
12 ACTG2 
actin, gamma 2, smooth 
muscle, enteric 1.51 5.00E-05 2.16E-03 
        
12 HINT1 
histidine triad nucleotide 
binding protein 1 1.51 5.00E-05 2.16E-03 
    +   
12 KRT7 keratin 7 -1.52 5.00E-05 2.16E-03         
12 SCIN scinderin -1.52 5.00E-05 2.16E-03         
12 PCP4 Purkinje cell protein 4 -1.53 5.00E-05 2.16E-03       + 
12 TGFBR3 
transforming growth 
factor, beta receptor III -1.54 5.00E-05 2.16E-03 
+ + + + 
12 HOXB4 homeobox B4 -1.57 5.00E-05 2.16E-03         
12 NRP2 neuropilin 2 -1.61 5.00E-05 2.16E-03 +   +   
12 ANXA2 annexin A2 -1.65 5.00E-05 2.16E-03         
12 MT4 metallothionein 4-like  -1.68 5.00E-05 2.16E-03         
12 TBX22 T-box 22 -1.69 5.00E-05 2.16E-03   +   + 
12 PLCXD1 
phosphatidylinositol 
specific phospholipase C X 
domain containing 1 -1.72 5.00E-05 2.16E-03 
        
12 NTN1 netrin 1 -1.73 5.00E-05 2.16E-03         
12 T 
T, brachyury homolog 
(mouse) -1.82 5.00E-05 2.16E-03 
+       
12 KRT17 
keratin, type I cytoskeletal 
14-like(LOC100858439) -1.84 5.00E-05 2.16E-03 
        
12 Pou5f3 
POU domain class 5 
transcription factor 3 -1.92 5.00E-05 2.16E-03 
        




2 -2.09 5.00E-05 2.16E-03 
        
12 CDH20 cadherin 20, type 2 -2.14 5.00E-05 2.16E-03         
12 EPAS1 
endothelial PAS domain 
protein 1 -2.17 5.00E-05 2.16E-03 
+ +   + 
12 COL3A1 collagen, type III, alpha 1 -2.23 5.00E-05 2.16E-03 +       
12 AQP1 aquaporin 1 -2.34 5.00E-05 2.16E-03         
12 OTX2 orthodenticle homeobox 2 -2.54 5.00E-05 2.16E-03   + +   
12 RBP riboflavin binding protein -2.79 5.00E-05 2.16E-03         
12 GUCA2B 
guanylate cyclase activator 
2B (uroguanylin) -2.97 5.00E-05 2.16E-03 
        
12 CDX1 caudal type homeobox 1 -3.14 5.00E-05 2.16E-03         
12 CDX4 caudal type homeobox 4 -3.18 5.00E-05 2.16E-03         
12 CHRD chordin -3.38 5.00E-05 2.16E-03         
12 PDLIM3 PDZ and LIM domain 3 -3.70 5.00E-05 2.16E-03 +     + 





12 RBP4 retinol binding protein 4 -3.74 5.00E-05 2.16E-03         
12 HOXB8 homeobox B8 -3.76 5.00E-05 2.16E-03         
12 APOB apolipoprotein B -5.26 5.00E-05 2.16E-03 +       
14 GUCA2B 
guanylate cyclase activator 
2B (uroguanylin) 5.27 5.00E-05 1.23E-03 
        
14 RBP4 retinol binding protein 4 2.49 5.00E-05 1.23E-03 +       
14 SLC7A9 
Solute Carrier Family 7 
Member 9  2.39 4.50E-04 8.97E-03 
        
14 VIPR2 
Vasoactive Intestinal 
Peptide Receptor 2 1.99 1.35E-03 2.26E-02 
    +   
14 SULT1C3 
Sulfotransferase Family 1C 
Member 3 1.62 7.00E-03 8.66E-02 
        
14 GBP guanylate binding protein -1.57 4.55E-02 3.26E-01         
14 AKR1B10 
aldo-keto reductase family 
1, member B10 (aldose 
reductase) -1.59 4.15E-03 5.72E-02 
        
14 OVAL ovalbumin (SERPINB14) -1.95 4.80E-03 6.40E-02         
Table 1.  Filtered Differentially Expressed Genes and Genetic Association 
Database Analysis.     
All DEGs were filtered for significance and a >1.5 fold or < -1.5 fold change in 
expression. GAD analysis was conducted to determine associated diseases. 
 
Further, pathway enrichment analysis (KEGG) demonstrated an 
overrepresentation of genes involved in cardiac muscle contraction and 
adrenergic signaling in cardiomyocytes with a 2-fold expression increase from 
HH10 to HH12. With longer exposure to PHE (HH 14), pathways in cellular 
processes including migration, proliferation, metabolism, and survival are 
significantly affected. Strikingly, biological themes from the gene ontology (GO) 
analysis included ventricular cardiac muscle tissue morphogenesis (HH10, genes 
= 5, p ≤ 1.74 x 10-6; HH12, genes = 6, p ≤ 1.92 x 10-5), cardiac muscle contraction 





(HH10, genes = 3, p ≤ 7.43 x 10-3; HH12, genes = 6, p ≤ 1.11 x 10-4), regulation of 
muscle contraction (HH10, genes = 3, p = 7.49 x 10-4 ; HH12, genes = 3, p ≤ 1.13 x 
10-2), BMP signaling pathway involved in heart development (HH10, genes = 2, p 
= 1.75x 10-3, HH12, genes = 2, p=6.84 x 10-2 ), heart looping (HH12, genes=6, p= 6.00 
X 103, HH14, genes = 3, p= 2.00 x 10-2), and heart morphogenesis (HH12, genes=4, 
p= 1.39 x 10-2, HH14, genes = 2, p= 9.30 x 10-2.  Data shown in Table 2 for all 
resultant cardiac specific themes. 
Stage KEGG pathway Gene Count p-value 
HH10 Cardiac muscle contraction 6 1.14E-04 
HH10 Pentose phosphate pathway 3 1.38E-02 
HH10 Adrenergic signaling in cardiomyocytes 5 1.64E-02 
HH10 Fructose and mannose metabolism 3 2.50E-02 
HH12 Cardiac muscle contraction 13 3.59E-07 
HH12 Focal adhesion 19 2.50E-05 
HH12 Oxidative phosphorylation 14 8.23E-05 
HH12 Tight junction 11 6.34E-03 
HH12 Regulation of actin cytoskeleton 13 1.28E-02 
HH12 Adrenergic signaling in cardiomyocytes 10 1.64E-02 
HH12 Dorso-ventral axis formation 4 3.38E-02 
HH14 Fructose and mannose metabolism 4 8.60E-04 
HH14 Galactose metabolism 4 9.50E-04 
HH14 Focal adhesion 6 5.70E-03 
HH14 Pentose and glucoronate interconversions 3 6.40E-03 
HH14 Glycerolipid metabolism 3 4.50E-02 
Stage Gene Ontology-Cardiac Specific Enriched Go Terms Gene Count p-value 
HH10 
Ventricular cardiac muscle tissue morphogenesis 
5 1.74E-06 
HH12 6 1.92E-05 
HH12 Regulation of heart rate 6 3.20E-05 
HH10 Cardiac muscle contraction 3 7.43E-03 





HH12 6 1.11E-04 
HH10 
Regulation of muscle contraction 
3 7.49E-04 
HH12 3 1.13E-02 
HH12 Heart development 12 5.72E-04 
HH12 
Regulation of cardiac muscle contraction by regulation of the release 
of sequestered calcium ion 
3 3.54E-03 
HH12 Regulation of myotube differentiation 3 3.54E-03 
HH10 
BMP signaling pathway involved in heart development 
2 1.75E-02 








HH14 2 9.30E-02 
HH12 Cardiac myofibril assembly 4 1.32E-03 
HH12 Artery morphogenesis 4 5.59E-03 
HH12 Atrial septum morphogenesis 3 2.94E-02 
HH12 Cardiac left ventricle formation 2 6.84E-02 
HH12 Myoblast fusion 3 4.52E-02 
HH12 Patterning of blood vessels 4 4.42E-02 
HH12 Positive regulation of angiogenesis 6 2.49E-02 
HH12 Positive regulation of myoblast differentiation 3 8.34E-02 
HH12 Angiogenesis 9 1.46E-02 
HH12 Positive regulation of myotube differentiation 3 2.26E-02 
HH12 
Regulation of ventricular cardiac muscle cell membrane 
repolarization 
3 2.26E-02 
HH12 Vasculogenesis 5 2.40E-02 
Table 2.  Functional Annotation HH10, 12, and 14.  
DAVID was utilized to perform KEGG and GO analysis. Themes at each stage in 
development as well as gene number and significance are displayed. GO analysis 
is limited to cardiac specific themes. 
 





Role of Retinoic Acid (RA) in MPKU 
As the role of RA in MPKU has not been previously addressed in the 
literature, we further investigated gene expression in RA metabolism and target 
response. We analyzed 81 genes (Supplemental Figure 12) and we observed 42 
genes with >1.5 or < -1.5 fold change in expression. We observed a total of 4 genes 
were up-regulated in response to PHE and the remaining 38 were down 
regulated.  Combining data from RNA-Seq (Supplemental Table 1) and qRTPCR 
(Supplemental Figure 12), notably, 15 unique genes with a significant role in 
Retinoic Acid (RA) metabolism and transport (HH10 = 4 genes, HH12 = 5 genes, 
HH14 = 14 genes).  Interestingly, this observation was confirmed in pathway 
analysis (HH12, cellular response to retinoic acid, genes = 5, p ≤ 7.55 x 10-3; HH14, 
RA receptor signaling pathway, genes = 2, p = 3.80X10-2) (Table 2 and 
Supplemental Table 2). 
Discussion 
In this study, we report the first elucidation of the molecular mechanisms of 
congenital heart defects in MPKU conducted at early developmental timepoints. 
We identified a total of 633 DEGs with provide an overabundance of possibilities 
for follow-up and interpretation. 





Most intriguing is the unexpected significant role of RA clearly demonstrated 
to increase over time. RA signaling is known to be involved in multiple 
embryonic developmental processes and is highly regulated throughout 
development [58-60].  Vitamin A (retinol) is oxidized it to its active metabolite RA 
in a developing embryo [26, 27].  RA is then able to act as a transcription factor by 
entering the nucleus through nuclear receptors to induce developmental gene 
expression or repression [25]. 
Not surprisingly then, perturbations in RA can lead to cardiac defects 
including TGA, muscular VSDs, DORV, membranous VSD, PTA and aortic arch 
arteries anomalies [as reviewed in [32, 33, 61]. These type of defects are very 
similar to those seen in MPKU associated CVMs in mouse and human [12, 45]. 
Strikingly, MPKU has often been compared to Fetal Alcohol Syndrome (FAS) 
due to their similar facial dysmorphologies (with many clinicians noting they are 
indistinguishable upon examination) [46]. One proposed mechanism for the 
development of FAS is the competitive inhibition of RA metabolism with 
preference for ethanol detoxification [62-65]. Thus, the clinical features of FAS are 
due to decreased presence of RA and our findings demonstrate downregulation of 





gene expression directly in RA pathways are associated with CVM development 
in a model of MPKU. 
One may predict that subsequent downstream pathways induced by RA may 
be affected as well. The increased effect on the RA pathway over these stages 
correlates with the increased demand for RA metabolism for the developing 
embryo [23, 31, 65]. At HH 10 the need for RA metabolism is less than in HH 12 
and 14. By HH 14 the need for RA metabolism is evident in the analysis of the 
gene expression functioning in transport, metabolism, and catabolism of RA.  A 
potential explanation for this is that PHE interferes with the conversion to RA and 
results in a deficit of nuclear RA, thus causing transcriptional increase for carrier 
proteins Retinol Binding Protein 4 (RBP4) and Transthyretin (TTR) to alleviate the 
deficit. Furthermore, Cytochrome P450 Family 26 (CYP26) proteins are 
downregulated, indicating that RA is not undergoing catabolism and elimination 
from the cell is not necessary. This would support the lack of RA availability for 
catabolism because it is not metabolized from retinol by Alcohol Dehydrogenase 
1C (ADH1C) because of decreased levels of substrate (Figure 3). Additionally, this 
theory is supported by the similarity of defects observed in human and animal 
models of Vitamin A Deficiency (VAD) and MPKU [66-68]. 






Figure 3. Retinoic Acid Metabolism at HH14. 
DEGs and qRTPCR results for HH14 of RA metabolism genes and transporters. 
Data from RNA-Seq denoted with 1 asterisk and qRTPCR with 2 asterisk. 
 
These findings lead to many additional questions. At this point, it is 
unclear whether perturbing the RA pathway is the only cause of MPKU 
associated CVMs, but there is sufficient evidence to warrant further investigation. 
In-vitro experiments with RA inhibitors to investigate cellular migration and 
proliferation are a logical next step with additional biochemical experiments to 
determine enzyme inhibition. One limitation in this study is the known 
phenotypic variability and incomplete penetrance that occur in MPKU that can 





result in small gene expression difference but have a significant spectrum of 
developmental effects. 
Conclusion 
Here, we report the first elucidation of the molecular mechanisms of 
congenital heart defects in MPKU conducted at early developmental timepoints. 
We provide evidence suggesting a link between PHE exposure and the alteration 
of RA pathway.  
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CHAPTER 3. In-vivo Molecular Gene Expression Analysis 
Introduction 
In developmental biology in-situ hybridization (ISH) is a molecular 
biology technique used to investigate qualitative changes in gene expression in 
tissue. Most importantly, ISH is utilized to look at temporal and spatial changes 
in gene expression.   Small changes can lead to CMVs in the developing embryo; 
therefore, we used this molecular technique to visualize mRNA expression in the 
chick embryo.  Previously, ISH has been successfully established in the whole 
chick embryo [69-71].  Additionally, a database of ISH is published on GEISHA 
(Gallus Expression In- Situ Hybridization Analysis) and can be used as a reference 
for validation of probes.  After analysis of RNA-Seq data from HH14, we sought 
to establish ISH in the lab.  Therefore, we cloned genes of interest for ISH from 
the RA pathway and genes of known biological significance in heart development 
for future analysis of heart defect (Table 3).  Here in we present two probes for 
HH14 for Fibroblast Growth Factor 8 (FGF8) and Cellular Retinoic Acid Binding 
Protein 1 (CRABP1).  FGF8 was used in ISH because of its known role in CVMs 
involving the cardiac outflow tract and CRABP1 was DE in RNA-Seq and 
qRTPCR data. 





CRABP1 expression results in an intracellular binding protein with a 
specific affinity for RA.  It has similar homology to CRBP which binds to retinol.  
CRABP1 functions among CRABP2, CRBP1-3, STRA6, FABP5, TTR, and RBP4, 
which all function in Vitamin A transport through retinol or RA to cells from the 
serum to intracellular transport regulating retinoid homeostasis. CRABP1 
functions in directing RA catabolism and delivery to nuclear receptors at which 
point RA can act as a transcription factor [72].  CRABP1 is expressed in multiple 
tissues and functions in regulating RA concentrations. CRABP1 may also 
contribute or RA toxicity when vitamin A is in excess by preventing the removal 
of metabolites [72]. 
FGF8 is part of the fibroblast growth factor (FGF) signaling pathway.  The 
FGF pathway is a molecular pathway known to function in early cell to cell 
communication in embryo development.  It has been previously reported that 
fluctuations in FGF8 signaling can negatively affect heart development [73]. With 
reduced FGF8 expression affecting heart development causing heart defects in the 
outflow tract and great vessels.  FGF8 signaling occurs through the pharyngeal 
arches (PA)  epithelia to the mesenchymal cells ,cNCCs, that migrate through the 
PA later forming the outflow tract and heart [74].  It has been previously shown 





by Macatee et, al, that ablating FGF8 signaling in the PA results in aortic arch and 
subclavian artery anomalies in 95% of mice with FGF8 ablated[75].  Additionally, 
ablating FGF8 in the PA ectoderm resulted in severe cardiac OFT septation, 
alignment, and vascular defects [75].   













cardiac patterning.  
Retinol acid 
signaling pathway 
Enzyme that catalyzes the synthesis of retinoic acid (RA) from 
retinaldehyde. Establish local embryonic retinoic acid levels which facilitate 
posterior organ development.  Embryonic RA synthesis is required for heart 










Intracellular protein that function in retinoic acid (RA) catabolism and 





CCGCAT  [71] 
FGF8 
Secondary heart 
field and outflow 
tract 
Secreted signaling protein with mitogenic and cell survival activities, and 
are involved in a variety of biological processes, including embryonic 




TCCCCT [72, 74] 
Isl1 Heart 
Transcription factor functioning in myocyte formation and function.  Isl1 is 





GGTAAC  [75] 
NKX 2.5 
Global patterning of 
the heart 
Transcription factor functioning in heart formation and development.  
Mutations in this genes cause multiple cardiac malformations including 




TTCTCT [76, 77] 
NPPA Atria 
Transcription Factor, Nppa is initiated in the developing atrial and later in 







Neural crest cell 
migration into the 
outflow tract 
Transmembrane receptor complex for ligand semaphorins, triggering a 
cellular signal transduction cascade that leads to axon or neural crest cell 
migration guidance, either repulsion or attraction.  Mutations in the is gene 







Vitamin A/ Retinol 
transport 
Specific carrier for retinol in the blood.  Retinol is delivered by RBP4 and 







Vitamin A/ Retinol 
transport 
Specific carrier for retinol in the blood.  Retinol is delivered by RBP4 and 




ATGGTAT  [81] 
Table 3.  Genes Cloned for In Situ Hybridization 





Materials and Methods 
RNA Extraction and Cloning 
 To prepare the cDNA library, RNA was extracted with PicoPure™ RNA 
Isolation Kit from 6 multistage embryos according to manufacturer’s protocol 
(Thermo Fisher Scientific, KIT0204); a cDNA library was constructed according to 
manufacturer’s protocol using 2 µg of cDNA (Fisher Scientific, Hampton, NH, US, 
Applied Biosystems, 4368814).  Primers for the gene of interest were used to 
amplify a 200-500 bp fragment.  Gene descriptions and primer sequences used are 
listed in Table 3.  The primers were amplified using polymerase chain reaction 
(PCR) and cDNA.    PCR products for the gene were generated using GoTaq then 
excised as the insert and gel purified (Promega Madison, WI, US, M7122) (Sigma 
St. Louis, MO, US, NA1111-1KT).  Purified DNA fragments were ligated into a 
pGEM-T vector (Supplemental Figure 9) (Fisher Scientific, PR-A1360) or pMini T 
2.0 (Supplemental Figure 10) from PCR cloning kit (NEB, Ipswich, MA, US, 
E1202S) and transformed into Escherichia coli Top10 competent cells according to 
manufacturer’s protocol (Fisher Scientific, C404010). Competent cells were 
cultured on LB agar plates with ampicillin (100mg/ml) and x-gal agar then 
incubated at 37°C overnight.  Single white colonies were selected when applicable 
and the insert was confirmed using colony PCR.  Colonies with inserts were 





cultured in 4 ml Luria–Bertani (LB) liquid medium containing ampicillin (100 
mg/ml) and grown overnight 37°C. 
 The cultures were mini-prepped (Midsci, St. Louis, MO, US, IB47171) and 
sent for sequencing using primers for SP6 and T7 promoters at Oklahoma Medical 
Research Foundation (OK, USA). The sequences were analyzed using Snapgene 
(http://www.snapgene.com) and Blast (https://blast.ncbi.nlm.nih.gov/Blast.cgi) to 
confirm the presence of the insert and its orientation in relation to the SP6 and T7 
promoters. Using the location and orientation of the insert the antisense and sense 
promoters were determined. 
Plasmid Linearization and in vitro Transcription 
 The DNA quality and quantity was analyzed using a Nanodrop 
spectrophotometer (Thermo Scientific).  The confirmed plasmid was then maxi-
prepped (Sigma, NA0300-1KT).  The plasmid was then linearized upstream of 
both the SP6 and T7 promoters using 10 µg of plasmid and restriction enzymes 
(NEB).  Enzymes were incubated for 2 hrs to overnight at 37°C.  The linearization 
was confirmed on 0.7% agarose gel.  The DNA was ethanol precipitated and used 
for in vitro transcription reactions. 
 The linearized plasmid was purified using phenyl:choloroform:isoamyl 
alcohol and ETOH precipitation.  The linearized plasmid DNA was then used for 





in vitro transcription reaction. In separate reactions for SP6 and T7 promoters, 1 µg 
of the linearized plasmid DNA was incubated with either SP6 polymerase (Fisher 
Scientific, FEREP0131) or T7 polymerase (Sigma, 10881767001) and RNAse 
inhibitor (Fisher Scientific, 10-777-019) to transcribe riboprobes for the antisense 
and sense strands with labeled digoxigenin (DIG) oligonucleotides (Sigma 
11277073910) according to manufacturer’s protocol.  The riboprobes were then 
checked for synthesis using 0.7% agarose gel electrophoresis. The riboprobe was 
then purified and ethanol precipitated.  Riboprobes were stored -80°C for in situ 
hybridization. 
Injections and Incubation Conditions of Embryos 
Fertilized white leghorn chicken eggs were obtained from Texas A&M 
Poultry Sciences.  Eggs were incubated at 37.2˚C and 50% humidity until HH 6.  
For injections eggs were removed from the incubator and the shell of the eggs was 
sterilized using a 70% ethanol. Using the 16 gauge needle, a small hole was drilled 
at the blunt end of the egg.  Eggs were treated with either sterile filtered 2.5 mM 
PHE or vehicle control (1 x PBS) through the blunt end of the egg (yolk injection).  
A 27 gauge needle was inserted into the hole and 200 µl of carrier vehicle or 2.5 
mM PHE was injected as described in the egg yolk Drake, et al [50]. After yolk 
injection the hole in the shell was sealed with tape and the embryos were further 





incubated until HH14. At HH14, the whole embryo was dissected out of the yolk, 
rinsed with 1xPBS.  Embryos were then fixed for 2 hours in 4% PFA at 4°C. 
In-situ Hybridization 
 The samples underwent wholemount in situ hybridization (WISH) 
experiments as described in [76].  WISH was performed on at least 3 embryos each 
from the vehicle control and PHE treated groups using both antisense and sense 
riboprobes.  Fixed embryos were incubated with 10 mg/ml proteinase K and re-
fixed with 0.02% glutaraldehyde and 4% paraformaldehyde.  Embryos were 
acclimated in hybridization buffer without probe for 1hr before adding 
riboprobes.  Hybridization with digoxigenin labeled riboprobes under stringent 
conditions (2X SSC and 50% formamide) for 2-5 days (depending on probe 
properties).  After incubation with riboprobes, embryos were extensively washed 
and blocked (Sigma 11096176001) prior to adding anti-DIG antibody.  Embryos 
were incubated in 1:1000 anti-digoxigenin AP- conjugate (DIG) (Sigma 
11093274910) overnight at 4˚C.  After extensive washing, embryos were then 
developed using 1:5 BM Purple with 10% PVA enhancement (Sigma 11093274910). 
Embryos were imaged with an Olympus stereomicroscope and an Olympus DP73 
camera.  Imaging software used was CellSens Entry from Olympus (Olympus, 
Tokyo, Japan).  mRNA levels are assessed qualitatively by comparing vehicle only 





control DIG labeling to DIG labeling in PHE treated embryos. 
Results and Discussion 
CRABP1 mRNA Expression in HH14 
In GEISHA an online database of published in situ work, CRABP1 has been 
previously reported at stage HH14 to be expressed in the pharyngeal arches and 
clefts (PA), ear and otic placode, face mesenchyme, spinal cord, and neural crest 
cells.  In PHE treated embryos we saw reduced expression in face mesenchyme.  
Expression was increased in the spinal cord, ear and otic placode, and neural crest 
in the PHE treated when compared to vehicle control embryos.  PA expression was 
low in both PHE and vehicle control embryos (Figure 4). 






Figure 4.  CRABP1 mRNA Expression in a Microenvironment of 2.5 mM PHE. 
Representative images of CRABP1 mRNA expression in vehicle control and PHE 
treated embryos, 2x magnification. 
FGF8 Expression Signaling in the Presence of PHE in HH14 
At stage HH14 FGF8 is expressed in the eye, face mesenchyme, midbrain, 
pharyngeal arches and clefts, somites, and tail [77].  In vehicle control embryos 





expression is similar.  When compared to PHE treated embryos there was reduced 
FGF8 expression in the face mesenchyme, midbrain, somites, pharyngeal arches 
(PA), and tail (Figure 5). 
Although there is no FGF8 expression in the heart, reduced expression of 
FGF8 signaling in the PA will negatively affect heart development of the chick 
embryo.  This is due to FGF8 expression inducing cNCCs to migrate in and 
populate the heart to later form the outflow tract and great vessels.  This reduced 
FGF8 expression will lead to CVMs in the developing chick heart.  Data from 
morphological studies in the lab show gross CVMs in the developing embryos 
(data not shown).  Considering the variable penetrance of MPKU phenotypes the 
effects of PHE on FGF8 may be the cause of varying morphological changes in the 
heart. 
In addition to CVMs, reduced expression of FGF8 in PA also leads to 
craniofacial defects.  As shown in PHE treated embryo expression in face 
mesenchyme is reduced and embryos frontonasal mass is noticeably shorter than 
vehicle control embryo.  Craniofacial defects have been previously reported when 
FGF8 signaling is ablated further lending to the effects of reduced FGF8 signaling 
on NCCs [75].  Overall, these data lend to PHE interfering with FGF8 signaling in 
the PA ultimately leading to CVMs and craniofacial defects. 






Figure 5.  FGF8 mRNA Expression in a Microenvironment of 2.5 mM of PHE. 
Representative images of FGF8 mRNA for vehicle control and PHE treated 
embryos, images A taken at 1.25x, B and C at 4x. 
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Chapter 4: Summary and Conclusions 
 To investigate cardiac malformations in developing chick embryos, we 
investigated alterations in gene expression during heart development in a 
microenvironment of PHE, a known teratogen.  Currently, there is no known 
mechanism of CVMs in MPKU and this work has identified a major 
developmental pathway affected.  We hypothesized that chick embryos exposed 
to high PHE will develop heart defects in the aortic arch arteries (AAA) and the 
outflow tract (OFT) resultant from alterations in gene and protein expression in 
the cardiac and surrounding tissue. To test this hypothesis, we used RNA-Seq, 
qRTPCR, and in situ hybridizations. 
We conducted whole transcriptome sequencing to analyze mRNA expression in 
the heart and thoracic region at HH10, 12, and 14, to generate potential targets for 
further investigation. We compared PHE treated embryos to vehicle control (PBS) 
embryos to determine DEGs in the heart. MPKU cardiac teratogenicity has no 
known cause; therefore, this RNA-Seq data has allowed us to better understand 
alterations in heart development in the presence of PHE.  Genes known for their 
significance in heart development and genes identified through RNA sequencing 
were further investigated through qRTPCR and in situ hybridization. 
 





Retinoic Acid Signaling Plays a Role in Heart Development. 
The metabolism of Vitamin A into RA occurs via multiple enzymes and in 
different locations throughout development. RA acts as a morphogen and serves 
as a major pathway in embryonic development.  In review of the literature, RA 
signaling is important in heart development and alterations either increasing or 
decreasing levels of RA can cause significant developmental defects. Perturbations 
in RA have led to cardiac defects including TGA, muscular VSDs, DORV, 
membranous VSD, PTA and aortic arch arteries anomalies [as reviewed in [61]]. 
These type of defects are very similar to those seen in MPKU associated CVMs in 
mouse and human, thus warranting further analysis [12, 45]. Based upon the RNA-
Seq data we have analyzed from HH stages 10, 12, and 14 (Supplemental Table 1) 
the RA pathway is consistently DE across all three stages.  Beginning with HH10, 
4 genes directly involved in the transport of RA are DE with additional DEGs 
affected by the RA pathway.  Both RBP4 and TTR are down-regulated indicating 
a decreased level of RA in the extracellular space and decreased transport of 
retinol to cell surface receptors.  Intracellular, downstream retinal and RA carriers, 
CRABP1 and FABP2 were also DE, with a downregulation of CRABP1. 
Gene expression testing for HH12 revealed the same genes DE as in HH10, 
but with the addition of ALDH1A2.  The ALDH1A2 gene encodes the enzyme 





responsible for the metabolism of retinal to RA.  In the presence of PHE at HH12, 
RBP4, TTR, and ALDH1A2 are downregulated and CRABP1 is upregulated. 
Additionally, HH14 embryos were analyzed with RNA-Seq and qRTPCR.   
In HH14, there are 10 DEGs found in the RA pathway including:  RBP4, TTR, 
GATA Binding Protein 4 (GATA4), CRABP1, Alcohol Dehydrogenase 1C 
(ADH1C), Aldehyde Dehydrogenase 1 Family Member A1 (ALDH1A1), Aldehyde 
Dehydrogenase 1 Family Member A3 (ALDH1A3), Cytochrome P450 Family 26 
Subfamily B Member 1 (CYP26B1), and Cytochrome P450 Family 26 Subfamily C 
Member 1 (CYP26C1).  At this time point we see an increase in gene expression for 
RBP, TTR, and ADH1C, an enzyme metabolizing retinol to retinal with the 
expression of all other genes in the pathway downregulated.  ALDH1A2 and 
ALDH1A1, retinal dehydrogenases are downregulated except for ALDH1A3, 
which is primarily expressed in tissues outside of the heart.  CRABP1 and the 
cytochromes are downregulated.  These changes indicate decreased nuclear 
availability of RA causing a decrease in target gene expression.    A potential 
explanation for this is that PHE interferes with ADH1C and prevents the 
conversion of retinol to retinal and a lack of nuclear RA, thus causing 
transcriptional increase for carrier proteins RBP4 and TTR to alleviate the deficit.  
Furthermore, CYP26 expression is downregulated, indicating that retinoic acid is 





not undergoing catabolism and elimination from the cell is not necessary.  This 
would support the lack of RA availability for catabolism because it is not 
metabolized from retinol by ADH1C because of decreased levels of substrate.  
Additionally, this theory is supported by the similarity of defects observed in 
human and animal models of VAD and MPKU. 
Overall the effect on the RA pathway increases from HH10, 12, and 14 as 
demonstrated by an increasing number of genes affected over time (Figure 6).  One 
may predict that subsequent downstream pathways induced by RA may be 
affected as well. The increased effect on the RA pathway over these stages 
correlates with the increased demand for RA metabolism for the developing 
embryo.  At HH10 the need for RA metabolism is less than in HH12 and 14.  By 
HH14 the need for RA metabolism is evident in the analysis of the gene expression 




Figure 6.  Retinoic Acid Pathway Differential Gene Expression. 
Differential genes expression shown from RNA Seq analysis for HH stages 10, 12, and 14, indicated by stage 
and *.  qRTPCR validation of HH14, indicated by **. 
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KEGG pathway analysis was used to understand the impact of all of the 
DEGs identified through RNA-Seq analysis. HH10 showed DE genes for heart 
related pathways including cardiac muscle contraction and adrenergic signaling 
in cardiomyocytes.  Additionally, DEGs input for KEGG analysis show the pentose 
phosphate pathway (PPP) and fructose and mannose metabolism were significant 
which may be due to the lack of metabolism of PHE causing other metabolites to 
build up.  Chick embryos lack Phenylalanine Hydroxylase (PAH), thus the ability 
to metabolize PHE until much later developmental stages than the stages studied.  
This increased amount of PHE offers an intermediate of the PPP, glycolysis, and 
mannose metabolism pathways.   For HH12 the same cardiac pathways in muscle 
contraction and adrenergic signaling are significant, but the number of genes in 
each pathway increases over 2- fold.  Embryos exposed to PHE longer display a 
significant effect on genes relevant to cardiac developmental processes including 
migration, proliferation, metabolism, and cell survival.  Additionally, we begin to 
see significant effects on genes in patterning of the dorso-ventral axis, including 
genes known to cause heart and neural tube defects. Proper axis formation is 
essential for organogenesis, heart development and the prevention of heart 
defects.  For HH14 similar pathways are significantly affected, functioning in 
metabolism, migration, proliferation, and cell survival. 





In addition to KEGG pathway analysis, we investigated significant genes 
with Gene Ontology (GO) enrichment analysis identifying biological themes.  In 
HH10, the largest numbers of genes are shown in DNA-templated transcription 
(11), multicellular organism development (7), negative regulation of neuron 
differential (6), ventricular cardiac muscle tissue morphogenesis (5), protein 
stabilization (4), and axon guidance (4).  Additional significant cardiac biological 
themes enriched were cardiac muscle contraction (3) and BMP signaling pathway 
involved in heart development (2). Furthermore, other terms of note that can easily 
be tied into heart function and development were: stem cell differentiation (3), 
positive regulation of mesenchymal cell apoptotic processes (2), signal 
transduction involved in regulation of gene expression (3), protein localization to 
juxtaparanode region of axon (2), Triglyceride catabolic process (2), and ion 
transport (2). 
For HH12, we observed an increase in the number of significant genes 
attributed to each biological theme and an increase in the overall themes 
identified.  Some of the biological themes identified in HH10 reoccur in HH12 with 
an increase in gene number such as DNA-templated transcription (36), 
multicellular organism development (17), axon guidance (13), cardiac muscle 
contraction (6), negative regulation of transcription regulatory region DNA 





binding (3), platelet aggregation (6), protein complex assembly (12), regulation of 
muscle contraction (3), signal transduction involved in regulation of gene 
expression (4), and ventricular cardiac muscle tissue morphogenesis (6).  Other 
pathways involved in cardiac function and development including: heart 
development (12), angiogenesis (9), regulation of heart rate (6), cardiac muscle 
contraction (6), heart looping (6), positive regulation of angiogenesis (6), cardiac 
myofibril assembly (4), artery morphogenesis (4), regulation of cardiac muscle 
contraction by regulation of the release of sequestered calcium ion, regulation of 
myotube differentiation (3), regulation of ventricular cardiac muscle cell 
membrane repolarization (3), atrial septum morphogenesis (3), and  myoblast 
fusion (3).  In addition to these themes, there are a large number of genes involved 
in transcription, translation, cell proliferation, migration, differentiation, and cell 
survival which could all contribute to the development of CVMs. 
In analysis of HH14, there is a smaller list of DAVID GO terms, this may be 
attributed to the reduced power of analysis due to the pooling of vehicle control 
samples and decreased sample size.  Additional sampling should be considered to 
investigate the effect of PHE at HH14.  Nonetheless, there are reoccurring themes 
in cellular migration, survival, and transcription such as negative regulation of 
extrinsic apoptotic signaling pathway via death domain receptors (4), cell-matrix 





adhesion (2), and transcription from RNA polymerase II promoter.  Additionally, 
significantly affected heart related themes include: response to calcium ion (3), 
heart looping (3), and heart morphogenesis (2). 
Focusing on RA signaling pathways observed in Enriched GO terms, RA 
signaling themes begin to show up in HH12 and continue to HH14.  In HH12 
cellular response to retinoic acid (5), and in HH state 14 there is retinoic acid 
receptor signaling pathway (2), and retinol metabolic process (2, p-value 0.063). 
In-vivo analysis by in situ hybridization was conducted on several genes 
from the RA pathway and genes with a known role in heart development. 
Sequences were cloned into DNA expression vectors to be transcribed into labeled 
probes for future mRNA analysis.  Initial in-situ analysis of CRABP1 and FGF8 
indicates changes of mRNA expression that warrant further investigations of 
additional stages including HH10, 12, and 14.  It is plausible that changes in 
expression may be too subtle to detect for some of the genes of the RA pathway. 
This work has identified potential pathways to determine the mechanism(s) 
of CVMs in MPKU that were previously unknown and not investigated.  In 
combination, the RNA-Seq and qRTPCR data have pointed to PHE perturbing the 
RA pathway, a known pathway significant in heart development.  This data only 
begins to elucidate the mechanism by which PHE is perturbing the RA pathway 





and to what extent.  Therefore, these investigations provide solid foundation for 
future experiments.  Historically, MPKU has shown phenotypic variability and 
incomplete penetrance, therefore gene expression fluctuation and small 
differences could cause a spectrum of developmental defects.  This observation 
leads to many additional questions that must be asked and investigated.  First, the 
effect of PHE on the RA pathway can be investigated with in-vitro experiments 
using known RA inhibitors such as DEAB to investigate cellular migration and 
proliferation.  Secondly, using luciferase reporter systems PHE interference can be 
further explored in-vitro by using a RA response element.  Third, additional genes 
can be studied using in-situ probes to analyze mRNA expression in the presence 
of PHE.    Finally, biochemical experiments can be performed to investigate if PHE 
is competitively inhibiting enzymes such as ADH in the retinoic acid pathway.  At 
this point, it is unclear whether perturbing the RA pathway is the only cause of 
MPKU associated CVMs, but there is sufficient evidence to investigate further. 








Supplemental Figure 1.   Per Base Sequence Quality of HH Stages 10 and 12. 
Representative graph showing per base pair quality of sequencing for HH stages 
10 and 12.  First 9 bases were trimmed and removed from analysis. 
 
 






Supplemental Figure 2.  Per Base Sequence Quality of HH14. 
Representative graph showing per base pair quality of sequencing of HH14.  First 










Supplemental Figure  3.   Per Sequence Quality Scores for HH10 and 12. 
Representative Phred score of sequencing for HH stages 10 and 12.  The average 
quality per sequence passed quality control testing. 






Supplemental Figure 4.  Per Sequence Quality Scores for HH14. 
Representative Phred score of sequencing for HH14.  The average quality per 













Supplemental Figure 5.  Per Base Sequence Content HH10 and 12. 
Representative chart depicting bases in sequences for HH10 and 12, indicating that 













Supplemental Figure 6.  Per Base Sequence Content for HH14. 
Chart depicting bases in sequences for HH14, indicating that first 6 bases needed 
to be removed from analysis. 






Supplemental Figure 7.  Per Sequence GC Content for HH10 and 12. 
Representative theoretical distribution of G and C base content in sequencing for 












Supplemental Figure 8.  Per Sequence GC Content for HH14. 
Representative theoretical distribution of G and C base content in sequencing for 
HH14. 
 







Supplemental Figure 9.  Map for p-GEM-T plasmid. 








































Supplemental Figure 10.  Map for p-Mini-T 2.0 plasmid. 
Map indicating restriction sites upstream of SP6 and T7 promoters used for 
transcription. 






Supplemental Figure 11.  Workflow of sample processing and bioinformatics 
analysis. 
All samples were processed as outlined as outlined in Figure 3.  TOPHAT was 
updated to HISAT2.  HH stages 10 and 12 were aligned using HISAT2 whereas, 
TOPHAT was used for HH14. 
 






Supplemental Figure 12.  QRTPCR Figure-Gene List-fold change. 
Gene expression of RA pathway genes with a >1.5 fold or < -1.5 fold change. Fold change displayed in log2 scale. 
 






Significant Differentially Expressed Genes for HH10-12-14 
Stage Gene Description log2 fold change p-value q-value 
HH10 AK1 adenylate kinase 1 -1.22 5.00E-05 5.37E-03 
HH10 ALDOB aldolase B, fructose-bisphosphate -2.86 5.00E-05 5.37E-03 
HH10 APC2 adenomatosis polyposis coli 2 1.60 5.00E-05 5.37E-03 
HH10 APOA1 apolipoprotein A-I -1.75 5.00E-05 5.37E-03 
HH10 APOB apolipoprotein B -2.97 5.00E-05 5.37E-03 
HH10 APOC3 apolipoprotein C3 -1.67 5.00E-05 5.37E-03 
HH10 ASTL astacin-like metallo-endopeptidase (M12 family) -1.67 5.00E-05 5.37E-03 
HH10 C5H11orf31 selenoprotein H -1.11 5.00E-05 5.37E-03 
HH10 CRABP1 cellular retinoic acid binding protein 1 -1.75 5.00E-05 5.37E-03 
HH10 DBX1 developing brain homeobox 1 3.22 5.00E-05 5.37E-03 
HH10 FABP2 Fatty Acid Binding Protein 2 down 5.00E-05 5.37E-03 
HH10 FBP1 fructose-1,6-bisphosphatase 1 -3.59 5.00E-05 5.37E-03 
HH10 FGA fibrinogen alpha chain -1.88 5.00E-05 5.37E-03 
HH10 GPR34 G protein-coupled receptor 34 up 5.00E-05 5.37E-03 
HH10 HAND1 heart and neural crest derivatives expressed 1 -1.41 5.00E-05 5.37E-03 
HH10 HBE hemoglobin subunit epsilon -4.33 5.00E-05 5.37E-03 
HH10 HBG1 hemoglobin beta, subunit rho -4.52 5.00E-05 5.37E-03 
HH10 HSPB1 heat shock protein family B (small) member 1 -1.34 5.00E-05 5.37E-03 
HH10 ID1 
inhibitor of DNA binding 1, dominant negative helix-loop-
helix protein 
-1.10 5.00E-05 5.37E-03 
HH10 PIGB PIGB opposite strand 1 -1.29 5.00E-05 5.37E-03 
HH10 AKR1BL aldo-keto reductase family 1 member B1-like 3.97 5.00E-05 5.37E-03 
HH10 LRRN1 leucine rich repeat neuronal 1 1.30 5.00E-05 5.37E-03 
HH10 MRPL41 mitochondrial ribosomal protein L41 -1.17 5.00E-05 5.37E-03 





HH10 MT4 metallothionein 4 -1.75 5.00E-05 5.37E-03 
HH10 MYL2 myosin, light chain 2, regulatory, cardiac, slow -2.04 5.00E-05 5.37E-03 
HH10 MYL3 myosin, light chain 3, alkali; ventricular, skeletal, slow -2.27 5.00E-05 5.37E-03 
HH10 NDUFA1 NADH:ubiquinone oxidoreductase subunit A1 -1.39 5.00E-05 5.37E-03 
HH10 NIP7 NIP7, nucleolar pre-rRNA processing protein -1.02 5.00E-05 5.37E-03 
HH10 NKX2-1 NK2 homeobox 1 3.83 5.00E-05 5.37E-03 
HH10 NR2E1 nuclear receptor subfamily 2 group E member 1 4.44 5.00E-05 5.37E-03 
HH10 OCX36 BPI fold containing family B member 3 2.54 5.00E-05 5.37E-03 
HH10 OLIG3 oligodendrocyte transcription factor 3 3.46 5.00E-05 5.37E-03 
HH10 OPN4-1 photopigment melanopsin-like up 5.00E-05 5.37E-03 
HH10 OST4 
oligosaccharyltransferase complex subunit 4, non-
catalytic 
-1.19 5.00E-05 5.37E-03 
HH10 OTX2 orthodenticle homeobox 2 2.63 5.00E-05 5.37E-03 
HH10 PAX6 paired box 6 1.77 5.00E-05 5.37E-03 
HH10 PTGDS prostaglandin D2 synthase 21kDa -2.53 5.00E-05 5.37E-03 
HH10 RAX retina and anterior neural fold homeobox 3.90 5.00E-05 5.37E-03 
HH10 RBP riboflavin binding protein -3.12 5.00E-05 5.37E-03 
HH10 RBP4 retinol binding protein 4 -1.66 5.00E-05 5.37E-03 
HH10 RGN regucalcin -1.31 5.00E-05 5.37E-03 
HH10 SEPP1 selenoprotein P1 -2.32 5.00E-05 5.37E-03 
HH10 SLC16A3 
solute carrier family 16 (monocarboxylate transporter), 
member 3 
1.35 5.00E-05 5.37E-03 
HH10 SLCO4A1 
solute carrier organic anion transporter family member 
4A1 




1.85 5.00E-05 5.37E-03 
HH10 TGM4 transglutaminase 4 (prostate) -3.62 5.00E-05 5.37E-03 






translocase of inner mitochondrial membrane 10 
homolog (yeast) 
-1.18 5.00E-05 5.37E-03 
HH10 TNNC2 troponin C type 2 (fast) -1.91 5.00E-05 5.37E-03 
HH10 AMN amnion associated transmembrane protein -3.12 1.00E-04 9.37E-03 
HH10 ASS1 argininosuccinate synthase 1 -1.18 1.00E-04 9.37E-03 
HH10 CNTN2 contactin 2 (axonal) 1.25 1.00E-04 9.37E-03 
HH10 MAP6 microtubule associated protein 6 1.18 1.00E-04 9.37E-03 
HH10 MSX1 msh homeobox 1 -1.04 1.00E-04 9.37E-03 
HH10 TESC tescalcin -1.09 1.00E-04 9.37E-03 
HH10 USPL1 ubiquitin specific peptidase like 1 1.00 1.00E-04 9.37E-03 
HH10 KRT19 keratin 19 -1.01 1.50E-04 1.25E-02 
HH10 NFASC neurofascin 1.12 1.50E-04 1.25E-02 
HH10 RPS28 ribosomal protein S28 -1.15 1.50E-04 1.25E-02 
HH10 SLC2A1 
solute carrier family 2 (facilitated glucose transporter), 
member 1 
0.99 1.50E-04 1.25E-02 
HH10 SOX1 SRY (sex determining region Y)-box 1 1.21 1.50E-04 1.25E-02 
HH10 TNNT2 troponin T type 2 (cardiac) -1.25 1.50E-04 1.25E-02 
HH10 UBAP2 ubiquitin associated protein 2 2.00 1.50E-04 1.25E-02 
HH10 KRT17 keratin 17 -1.49 2.00E-04 1.56E-02 
HH10 MLN motilin up 2.00E-04 1.56E-02 
HH10 RTN1 reticulon 1 2.26 2.00E-04 1.56E-02 
HH10 TOMM6 translocase of outer mitochondrial membrane 6 -1.01 2.00E-04 1.56E-02 
HH10 LINGO1 leucine rich repeat and Ig domain containing 1 1.18 2.50E-04 1.84E-02 
HH10 MSX2 msh homeobox 2 -1.69 2.50E-04 1.84E-02 
HH10 PPIB peptidylprolyl isomerase B (cyclophilin B) -0.96 2.50E-04 1.84E-02 
HH10 SIX3 SIX homeobox 3 6.11 2.50E-04 1.84E-02 
HH10 AMBP alpha-1-microglobulin/bikunin precursor -3.05 3.00E-04 2.01E-02 





HH10 CALML4 calmodulin like 4 -1.23 3.00E-04 2.01E-02 
HH10 CYP3A7 cytochrome P450 A 37 -3.44 3.00E-04 2.01E-02 
HH10 EPAS1 endothelial PAS domain protein 1 -1.25 3.00E-04 2.01E-02 
HH10 FAM210B family with sequence similarity 210 member B 1.16 3.00E-04 2.01E-02 
HH10 MRPS21 mitochondrial ribosomal protein S21 -1.06 3.00E-04 2.01E-02 
HH10 NRXN1 neurexin 1 1.23 3.00E-04 2.01E-02 
HH10 COMMD4 COMM domain containing 4 -1.03 3.50E-04 2.23E-02 
HH10 ITIH2 inter-alpha-trypsin inhibitor heavy chain 2 -2.32 3.50E-04 2.23E-02 
HH10 MYLK myosin light chain kinase 1.11 3.50E-04 2.23E-02 
HH10 POLR2F polymerase (RNA) II subunit F(POLR2F) -0.95 3.50E-04 2.23E-02 
HH10 CDH20 cadherin 20, type 2(CDH20) -1.76 4.00E-04 2.43E-02 
HH10 DLX6 distal-less homeobox 6(DLX6) 1.97 4.00E-04 2.43E-02 
HH10 GJB1 gap junction protein, beta 1, 32kDa -1.21 4.00E-04 2.43E-02 
HH10 JARID2 jumonji and AT-rich interaction domain containing 2 0.94 4.00E-04 2.43E-02 
HH10 ELMO1 engulfment and cell motility 1 1.13 4.50E-04 2.61E-02 
HH10 HOXB8 homeobox B8 -1.60 4.50E-04 2.61E-02 
HH10 SRA1 steroid receptor RNA activator 1 -1.21 4.50E-04 2.61E-02 
HH10 TNNC1 troponin C type 1 (slow) -1.19 4.50E-04 2.61E-02 
HH10 ATP6AP1 ATPase H+ transporting accessory protein 1 1.05 5.00E-04 2.83E-02 
HH10 SRL sarcalumenin -1.46 5.00E-04 2.83E-02 
HH10 MYH7B myosin, heavy chain 7B, cardiac muscle, beta -1.15 5.50E-04 3.08E-02 
HH10 PPDPF 
pancreatic progenitor cell differentiation and 
proliferation factor 
-0.97 6.50E-04 3.60E-02 
HH10 CDC26 cell division cycle 26 -1.16 7.50E-04 4.07E-02 
HH10 NDFIP2 Nedd4 family interacting protein 2 0.89 7.50E-04 4.07E-02 
HH10 ADCK3 aarF domain containing kinase 3 0.87 8.00E-04 4.25E-02 





HH10 MIR1774 MIR1774 up 8.00E-04 4.25E-02 
HH10 BCAS2 breast carcinoma amplified sequence 2 -0.89 8.50E-04 4.43E-02 
HH10 KCNAB1 
potassium voltage-gated channel, shaker-related 
subfamily, beta member 1 
1.15 8.50E-04 4.43E-02 
HH10 DCTN6 dynactin subunit 6 -0.86 9.00E-04 4.59E-02 
HH10 SOX2 SRY (sex determining region Y)-box 2 1.19 9.00E-04 4.59E-02 
HH10 ATP5I 
ATP synthase, H+ transporting, mitochondrial Fo complex 
subunit E 
-0.90 9.50E-04 4.62E-02 
HH10 EXOC5 exocyst complex component 5 0.88 9.50E-04 4.62E-02 
HH10 MYL9 myosin, light chain 9, regulatory -0.90 9.50E-04 4.62E-02 
HH10 SNRPF small nuclear ribonucleoprotein polypeptide F -0.87 9.50E-04 4.62E-02 
HH10 TTR transthyretin -1.17 9.50E-04 4.62E-02 
HH10 EP400 E1A binding protein p400 0.89 1.00E-03 4.77E-02 
HH10 FAM136A family with sequence similarity 136 member A -0.86 1.00E-03 4.77E-02 
HH10 TF transferrin (ovotransferrin) -1.10 1.05E-03 4.92E-02 
HH10 UQCR11 ubiquinol-cytochrome c reductase, complex III subunit XI -0.93 1.05E-03 4.92E-02 
HH12 ACTC1 actin, alpha, cardiac muscle 1 1.19 5.00E-05 2.16E-03 
HH12 ACTG2 actin, gamma 2, smooth muscle, enteric 1.51 5.00E-05 2.16E-03 
HH12 ADCYAP1 adenylate cyclase activating polypeptide 1 (pituitary) 1.60 5.00E-05 2.16E-03 
HH12 AMY2A amylase, alpha 2A 1.41 5.00E-05 2.16E-03 
HH12 ANXA2 annexin A2 -1.65 5.00E-05 2.16E-03 
HH12 APOB apolipoprotein B -5.26 5.00E-05 2.16E-03 
HH12 AQP1 aquaporin 1 -2.34 5.00E-05 2.16E-03 
HH12 ASB12 ankyrin repeat and SOCS box containing 12 1.34 5.00E-05 2.16E-03 
HH12 ATP5I 
ATP synthase, H+ transporting, mitochondrial Fo complex 
subunit E 
1.04 5.00E-05 2.16E-03 





HH12 BASP1 brain abundant membrane attached signal protein 1 -1.19 5.00E-05 2.16E-03 
HH12 BRINP1 
bone morphogenetic protein/retinoic acid inducible 
neural-specific 1 
-1.28 5.00E-05 2.16E-03 
HH12 BVES blood vessel epicardial substance 1.34 5.00E-05 2.16E-03 
HH12 CAV3 caveolin 3 down 5.00E-05 2.16E-03 
HH12 CD93 CD93 molecule -1.23 5.00E-05 2.16E-03 
HH12 CDH20 cadherin 20, type 2 -2.14 5.00E-05 2.16E-03 
HH12 CDX1 caudal type homeobox 1 -3.14 5.00E-05 2.16E-03 
HH12 CDX4 caudal type homeobox 4 -3.18 5.00E-05 2.16E-03 
HH12 CHRD chordin -3.38 5.00E-05 2.16E-03 
HH12 COL3A1 collagen, type III, alpha 1 -2.23 5.00E-05 2.16E-03 
HH12 COLEC12 collectin sub-family member 12 -1.00 5.00E-05 2.16E-03 
HH12 COX7A2 cytochrome c oxidase subunit VIIa polypeptide 2 (liver) 0.95 5.00E-05 2.16E-03 
HH12 CRABP1 cellular retinoic acid binding protein 1 1.23 5.00E-05 2.16E-03 
HH12 CRYAB crystallin, alpha B 1.30 5.00E-05 2.16E-03 
HH12 CSRP3 cysteine and glycine-rich protein 3 (cardiac LIM protein) 1.43 5.00E-05 2.16E-03 
HH12 CTNNA3 catenin (cadherin-associated protein), alpha 3 1.39 5.00E-05 2.16E-03 
HH12 EEF1A2 eukaryotic translation elongation factor 1 alpha 2 1.09 5.00E-05 2.16E-03 
HH12 ENG endoglin -1.28 5.00E-05 2.16E-03 
HH12 EPAS1 endothelial PAS domain protein 1 -2.17 5.00E-05 2.16E-03 
HH12 ETS1 
v-ets avian erythroblastosis virus E26 oncogene homolog 
1 
-1.07 5.00E-05 2.16E-03 
HH12 FABP7 fatty acid binding protein 7, brain -1.03 5.00E-05 2.16E-03 
HH12 FKBP1B FK506 binding protein 1B, 12.6 kDa 1.23 5.00E-05 2.16E-03 
HH12 FLNB filamin B, beta -0.95 5.00E-05 2.16E-03 





HH12 FLT4 fms-related tyrosine kinase 4 -1.00 5.00E-05 2.16E-03 
HH12 FMOD fibromodulin -1.98 5.00E-05 2.16E-03 
HH12 GNG5 guanine nucleotide binding protein (G protein), gamma 5 1.00 5.00E-05 2.16E-03 
HH12 GTF2H5 general transcription factor IIH subunit 5 0.92 5.00E-05 2.16E-03 
HH12 GUCA2B guanylate cyclase activator 2B (uroguanylin) -2.97 5.00E-05 2.16E-03 
HH12 HAUS1 HAUS augmin like complex subunit 1 1.01 5.00E-05 2.16E-03 
HH12 HBE hemoglobin subunit epsilon 2.33 5.00E-05 2.16E-03 
HH12 HBG1 hemoglobin, beta 2.33 5.00E-05 2.16E-03 
HH12 HBG2 hemoglobin, beta 2.48 5.00E-05 2.16E-03 
HH12 HIC1 hypermethylated in cancer 1 -1.22 5.00E-05 2.16E-03 
HH12 HINT1 histidine triad nucleotide binding protein 12 1.51 5.00E-05 2.16E-03 
HH12 HOXB3 homeobox B3 -1.02 5.00E-05 2.16E-03 
HH12 HOXB4 homeobox B4 -1.57 5.00E-05 2.16E-03 
HH12 HOXB8 homeobox B8 -3.76 5.00E-05 2.16E-03 
HH12 HOXC8 homeobox C8 down 5.00E-05 2.16E-03 
HH12 HSPB1 heat shock protein family B (small) member 1 1.25 5.00E-05 2.16E-03 
HH12 IER3IP1 immediate early response 3 interacting protein 1 1.00 5.00E-05 2.16E-03 
HH12 IFI27L2 interferon, alpha-inducible protein 27-like 2 1.81 5.00E-05 2.16E-03 
HH12 IRX4 iroquois homeobox 4 1.37 5.00E-05 2.16E-03 
HH12 KRT14 keratin 14 -1.48 5.00E-05 2.16E-03 
HH12 KRT7 keratin 7 -1.52 5.00E-05 2.16E-03 
HH12 LIN28A lin-28 homolog A (C. elegans) -0.91 5.00E-05 2.16E-03 
HH12 KRT17 keratin, type I cytoskeletal 14-like(LOC100858439) -1.84 5.00E-05 2.16E-03 
HH12 AK6 adenylate kinase 6 0.97 5.00E-05 2.16E-03 
HH12 SDHAF2 succinate dehydrogenase complex assembly factor 2 0.85 5.00E-05 2.16E-03 






cytochrome c oxidase subunit 7B, mitochondrial-
like(LOC771947) 
0.98 5.00E-05 2.16E-03 
HH12 C14orf2 chromosome 14 open reading frame 2 0.96 5.00E-05 2.16E-03 
HH12 LSM5 
LSM5 homolog, U6 small nuclear RNA and mRNA 
degradation associated 
1.28 5.00E-05 2.16E-03 
HH12 LSP1 lymphocyte-specific protein 1 -1.09 5.00E-05 2.16E-03 
HH12 MAB21L2 mab-21-like 2 (C. elegans) -1.16 5.00E-05 2.16E-03 
HH12 MB myoglobin 1.78 5.00E-05 2.16E-03 
HH12 MEOX1 mesenchyme homeobox 1 -0.97 5.00E-05 2.16E-03 
HH12 MESP2 mesoderm posterior bHLH transcription factor 2 down 5.00E-05 2.16E-03 
HH12 MFI2 melanotransferrin -1.28 5.00E-05 2.16E-03 
HH12 MINOS1 mitochondrial inner membrane organizing system 1 0.97 5.00E-05 2.16E-03 
HH12 MSGN1 mesogenin 1 down 5.00E-05 2.16E-03 
HH12 MSX1 msh homeobox 1 -1.23 5.00E-05 2.16E-03 
HH12 MT4 metallothionein 4-like -1.68 5.00E-05 2.16E-03 
HH12 MYBPC3 myosin binding protein C, cardiac 1.19 5.00E-05 2.16E-03 
HH12 MYL1 myosin, light chain 1, alkali; skeletal, fast 1.18 5.00E-05 2.16E-03 
HH12 MYL2 myosin, light chain 2, regulatory, cardiac, slow 1.69 5.00E-05 2.16E-03 
HH12 MYL3 myosin, light chain 3, alkali; ventricular, skeletal, slow 1.49 5.00E-05 2.16E-03 
HH12 MYLK myosin light chain kinase -1.38 5.00E-05 2.16E-03 
HH12 NDUFA1 NADH:ubiquinone oxidoreductase subunit A1 1.17 5.00E-05 2.16E-03 
HH12 NKX2-5 NK2 homeobox 5 0.99 5.00E-05 2.16E-03 
HH12 NKX2-6 NK2 homeobox 6 1.18 5.00E-05 2.16E-03 
HH12 NPPB natriuretic peptide B 1.20 5.00E-05 2.16E-03 
HH12 NRP2 neuropilin 2 -1.61 5.00E-05 2.16E-03 
HH12 NTN1 netrin 1 -1.73 5.00E-05 2.16E-03 





HH12 OLFM1 olfactomedin 1 -1.13 5.00E-05 2.16E-03 
HH12 OTX2 orthodenticle homeobox 2 -2.54 5.00E-05 2.16E-03 
HH12 OXNAD1 oxidoreductase NAD-binding domain containing 1 1.02 5.00E-05 2.16E-03 
HH12 PCDHGC3 protocadherin gamma subfamily C, 3 -1.06 5.00E-05 2.16E-03 
HH12 PCP4 Purkinje cell protein 4 -1.53 5.00E-05 2.16E-03 
HH12 PDLIM3 PDZ and LIM domain 3 -3.70 5.00E-05 2.16E-03 
HH12 PFDN4 prefoldin subunit 4 0.96 5.00E-05 2.16E-03 
HH12 PLCXD1 
phosphatidylinositol specific phospholipase C X domain 
containing 1 
-1.72 5.00E-05 2.16E-03 
HH12 PLN phospholamban 1.83 5.00E-05 2.16E-03 
HH12 POPDC2 popeye domain containing 2 1.06 5.00E-05 2.16E-03 
HH12 PRPS2 phosphoribosyl pyrophosphate synthetase 2 -2.09 5.00E-05 2.16E-03 
HH12 Pou5f3 POU domain class 5 transcription factor 3 -1.92 5.00E-05 2.16E-03 
HH12 RASSF2 Ras association (RalGDS/AF-6) domain family member 2 -1.24 5.00E-05 2.16E-03 
HH12 RBM24 RNA binding motif protein 24 0.98 5.00E-05 2.16E-03 
HH12 RBP riboflavin binding protein -2.79 5.00E-05 2.16E-03 
HH12 RBP4 retinol binding protein 4 -3.74 5.00E-05 2.16E-03 
HH12 RGL1 ral guanine nucleotide dissociation stimulator-like 1 -0.97 5.00E-05 2.16E-03 
HH12 SCIN scinderin -1.52 5.00E-05 2.16E-03 
HH12 SELK selenoprotein K 0.92 5.00E-05 2.16E-03 
HH12 SEPP1 selenoprotein P1 -1.28 5.00E-05 2.16E-03 
HH12 SERPINI1 
serpin peptidase inhibitor, clade I (neuroserpin), member 
1 
1.75 5.00E-05 2.16E-03 
HH12 SLC4A1 solute carrier family 4, anion exchanger, member 1 1.70 5.00E-05 2.16E-03 
HH12 SMYD1 SET and MYND domain containing 1 0.99 5.00E-05 2.16E-03 
HH12 SRL sarcalumenin 1.19 5.00E-05 2.16E-03 





HH12 T T, brachyury homolog (mouse) -1.82 5.00E-05 2.16E-03 
HH12 TBX22 T-box 22 -1.69 5.00E-05 2.16E-03 
HH12 TCF15 transcription factor 15 (basic helix-loop-helix) -1.01 5.00E-05 2.16E-03 
HH12 TF transferrin (ovotransferrin) -1.12 5.00E-05 2.16E-03 
HH12 TGFBR3 transforming growth factor, beta receptor III -1.54 5.00E-05 2.16E-03 
HH12 TMEM167A transmembrane protein 167A 1.28 5.00E-05 2.16E-03 
HH12 TMEM207 transmembrane protein 207 down 5.00E-05 2.16E-03 
HH12 TNNC1 troponin C type 1 (slow) 1.42 5.00E-05 2.16E-03 
HH12 TNNC2 troponin C type 2 (fast) 1.74 5.00E-05 2.16E-03 
HH12 TOMM7 translocase of outer mitochondrial membrane 7 0.98 5.00E-05 2.16E-03 
HH12 TRIM55 tripartite motif containing 55 1.08 5.00E-05 2.16E-03 
HH12 TUBB1 tubulin, beta 1 class VI 1.39 5.00E-05 2.16E-03 
HH12 TYRO3 TYRO3 protein tyrosine kinase -0.88 5.00E-05 2.16E-03 
HH12 UTP15 UTP15, small subunit processome component 1.06 5.00E-05 2.16E-03 
HH12 ACTN4 actinin, alpha 4 -0.89 1.00E-04 3.89E-03 
HH12 ARPC1B actin related protein 2/3 complex subunit 1B -1.19 1.00E-04 3.89E-03 
HH12 CACNA2D1 
calcium channel, voltage-dependent, alpha 2/delta 
subunit 1 
1.22 1.00E-04 3.89E-03 
HH12 CBWD1 COBW domain containing 1 1.10 1.00E-04 3.89E-03 
HH12 LSM6 
LSM6 homolog, U6 small nuclear RNA associated (S. 
cerevisiae) 
0.94 1.00E-04 3.89E-03 
HH12 MRPS10 mitochondrial ribosomal protein S10 0.91 1.00E-04 3.89E-03 
HH12 NCOA1 nuclear receptor coactivator 1 -1.06 1.00E-04 3.89E-03 
HH12 NDUFB2 NADH:ubiquinone oxidoreductase subunit B2 0.95 1.00E-04 3.89E-03 
HH12 PITX1 paired-like homeodomain 1 -2.24 1.00E-04 3.89E-03 
HH12 SH3GL1 SH3-domain GRB2-like 1 -0.91 1.00E-04 3.89E-03 
HH12 SIN3A SIN3 transcription regulator family member A -0.94 1.00E-04 3.89E-03 





HH12 SOX9 SRY (sex determining region Y)-box 9 -1.38 1.00E-04 3.89E-03 
HH12 TXN thioredoxin 1.26 1.00E-04 3.89E-03 
HH12 AXIN2 axin 2 -1.20 1.50E-04 5.10E-03 
HH12 CINP cyclin dependent kinase 2 interacting protein 0.96 1.50E-04 5.10E-03 
HH12 CKS2 CDC28 protein kinase regulatory subunit 2 1.31 1.50E-04 5.10E-03 
HH12 DDX55 DEAD (Asp-Glu-Ala-Asp) box polypeptide 55 0.93 1.50E-04 5.10E-03 
HH12 FADS2 fatty acid desaturase 2 -0.92 1.50E-04 5.10E-03 
HH12 GATA2 GATA binding protein 2 -1.13 1.50E-04 5.10E-03 
HH12 GJA5 gap junction protein alpha 5 0.95 1.50E-04 5.10E-03 
HH12 IL17RD interleukin 17 receptor D -1.23 1.50E-04 5.10E-03 
HH12 LMOD2 leiomodin 2 1.15 1.50E-04 5.10E-03 
HH12 LOC420411 uncharacterized LOC420411 1.05 1.50E-04 5.10E-03 
HH12 MNX1 motor neuron and pancreas homeobox 1 -2.26 1.50E-04 5.10E-03 
HH12 MSX2 msh homeobox 2 -1.04 1.50E-04 5.10E-03 
HH12 MYH15 myosin, heavy chain 15 1.22 1.50E-04 5.10E-03 
HH12 PIWIL1 piwi-like 1 (Drosophila) -1.22 1.50E-04 5.10E-03 
HH12 SAMD11 sterile alpha motif domain containing 11 -1.06 1.50E-04 5.10E-03 
HH12 SEC61G Sec61 translocon gamma subunit 0.95 1.50E-04 5.10E-03 
HH12 SP1 Sp1 transcription factor -0.88 1.50E-04 5.10E-03 
HH12 TESC tescalcin 0.88 1.50E-04 5.10E-03 
HH12 UQCR11 ubiquinol-cytochrome c reductase, complex III subunit XI 0.97 1.50E-04 5.10E-03 
HH12 ADAM33 ADAM metallopeptidase domain 33 -1.20 2.00E-04 6.22E-03 
HH12 CLDN5 claudin 5 -1.31 2.00E-04 6.22E-03 
HH12 COX17 COX17 cytochrome c oxidase copper chaperone 0.82 2.00E-04 6.22E-03 
HH12 DNASE2B deoxyribonuclease II beta -1.44 2.00E-04 6.22E-03 
HH12 DRAXIN dorsal inhibitory axon guidance protein -0.97 2.00E-04 6.22E-03 





HH12 FUS FUS RNA binding protein -0.81 2.00E-04 6.22E-03 
HH12 NAA35 N(alpha)-acetyltransferase 35, NatC auxiliary subunit 0.86 2.00E-04 6.22E-03 
HH12 NREP neuronal regeneration related protein 0.83 2.00E-04 6.22E-03 
HH12 SLC9A8 solute carrier family 9 member A8 0.99 2.00E-04 6.22E-03 
HH12 TARS threonyl-tRNA synthetase 0.93 2.00E-04 6.22E-03 
HH12 TFAP2B transcription factor AP-2 beta -1.19 2.00E-04 6.22E-03 
HH12 TFCP2 transcription factor CP2 -0.84 2.00E-04 6.22E-03 
HH12 TTR transthyretin -0.87 2.00E-04 6.22E-03 
HH12 XPA xeroderma pigmentosum, complementation group A 0.90 2.00E-04 6.22E-03 
HH12 ANGPTL3 angiopoietin like 3 -1.64 2.50E-04 7.46E-03 
HH12 C15ORF15 ribosomal L24 domain containing 1 0.91 2.50E-04 7.46E-03 
HH12 CYGB cytoglobin -1.48 2.50E-04 7.46E-03 
HH12 GCSH glycine cleavage system protein H (aminomethyl carrier) 0.81 2.50E-04 7.46E-03 
HH12 LMNB2 lamin B2 -0.87 2.50E-04 7.46E-03 
HH12 TMOD1 tropomodulin 1 0.84 2.50E-04 7.46E-03 
HH12 VCL vinculin -0.87 2.50E-04 7.46E-03 
HH12 ALG6 ALG6, alpha-1,3-glucosyltransferase 0.93 3.00E-04 8.42E-03 
HH12 BRIX1 BRX1, biogenesis of ribosomes 1.01 3.00E-04 8.42E-03 
HH12 CXCL12 chemokine (C-X-C motif) ligand 12 -1.30 3.00E-04 8.42E-03 
HH12 ETV5 ets variant 5 -0.91 3.00E-04 8.42E-03 
HH12 FLT1 fms-related tyrosine kinase 1 -0.98 3.00E-04 8.42E-03 
HH12 MYH7B myosin, heavy chain 7B, cardiac muscle, beta 1.07 3.00E-04 8.42E-03 
HH12 POPDC3 popeye domain containing 3 1.06 3.00E-04 8.42E-03 
HH12 SALL3 spalt-like transcription factor 3 -0.96 3.00E-04 8.42E-03 





HH12 SEPT19  -0.87 3.00E-04 8.42E-03 
HH12 SOHO-1 sensory organ homeobox protein SOHo 1.31 3.00E-04 8.42E-03 
HH12 TNNT2 troponin T type 2 (cardiac) 1.13 3.00E-04 8.42E-03 
HH12 ANGPT1 angiopoietin 1 1.04 3.50E-04 9.41E-03 
HH12 ARID3B actin related protein 2/3 complex, subunit 1B, 41kDa -0.86 3.50E-04 9.41E-03 
HH12 DAG1 dystroglycan 1 (dystrophin-associated glycoprotein 1) -0.79 3.50E-04 9.41E-03 
HH12 DPYSL2 dihydropyrimidinase-like 2 -0.78 3.50E-04 9.41E-03 
HH12 MYH9 myosin, heavy chain 9, non-muscle -0.89 3.50E-04 9.41E-03 
HH12 PTK2 protein tyrosine kinase 2 -0.78 3.50E-04 9.41E-03 
HH12 ST3GAL1 ST3 beta-galactoside alpha-2,3-sialyltransferase 1 -0.93 3.50E-04 9.41E-03 
HH12 SULT1C3 sulfotransferase family, cytosolic, 1C, member 3 -1.96 3.50E-04 9.41E-03 
HH12 CNP 2',3'-cyclic nucleotide 3' phosphodiesterase -1.02 4.00E-04 1.04E-02 
HH12 DLL1 delta-like 1 (Drosophila) -1.14 4.00E-04 1.04E-02 
HH12 EFNB2 ephrin-B2 -1.43 4.00E-04 1.04E-02 
HH12 GLI1 GLI family zinc finger 1 -0.92 4.00E-04 1.04E-02 
HH12 LSM3 
LSM3 homolog, U6 small nuclear RNA and mRNA 
degradation associated 
0.83 4.00E-04 1.04E-02 
HH12 SREBF1 sterol regulatory element binding transcription factor 1 -0.84 4.00E-04 1.04E-02 
HH12 COX20 COX20 cytochrome c oxidase assembly factor 0.88 4.50E-04 1.12E-02 
HH12 EFNA2 ephrin-A2 -1.33 4.50E-04 1.12E-02 
HH12 ETS2 
v-ets avian erythroblastosis virus E26 oncogene homolog 
2 
-0.94 4.50E-04 1.12E-02 
HH12 FOSL2 FOS like antigen 2 -2.73 4.50E-04 1.12E-02 
HH12 IRF8 interferon regulatory factor 8 -1.08 4.50E-04 1.12E-02 






lanosterol synthase (2,3-oxidosqualene-lanosterol 
cyclase) 
-0.87 4.50E-04 1.12E-02 
HH12 PAX7 paired box 7 -1.58 4.50E-04 1.12E-02 
HH12 PCDH15 protocadherin-related 15 1.28 4.50E-04 1.12E-02 
HH12 SNRPF small nuclear ribonucleoprotein polypeptide F 0.86 4.50E-04 1.12E-02 
HH12 FSCN1 fascin actin-bundling protein 1 -0.78 5.00E-04 1.22E-02 
HH12 GSTK1 glutathione S-transferase kappa 1 0.82 5.00E-04 1.22E-02 
HH12 LAMB2 laminin, beta 2 (laminin S) 1.02 5.00E-04 1.22E-02 
HH12 SEPT15  0.77 5.00E-04 1.22E-02 
HH12 TRAPPC13 trafficking protein particle complex 13 1.00 5.00E-04 1.22E-02 
HH12 EFNB1 ephrin-B1 -0.77 5.50E-04 1.29E-02 
HH12 AKR1B1L aldo-keto reductase family 1 member B1-like 1.01 5.50E-04 1.29E-02 
HH12 DYL1 dynein light chain 1 cytoplasmic 0.82 5.50E-04 1.29E-02 
HH12 NR5A2 nuclear receptor subfamily 5, group A, member 2 -1.59 5.50E-04 1.29E-02 
HH12 PDZK1IP1 PDZK1 interacting protein 1 -1.52 5.50E-04 1.29E-02 
HH12 RALBP1 ralA binding protein 1 -0.80 5.50E-04 1.29E-02 
HH12 TBX5 T-box 5 0.80 5.50E-04 1.29E-02 
HH12 TCF3 transcription factor 3 -0.75 5.50E-04 1.29E-02 
HH12 FZR1 fizzy/cell division cycle 20 related 1 -0.85 6.00E-04 1.38E-02 
HH12 FDFT1 farnesyl-diphosphate farnesyltransferase 1 -0.77 6.00E-04 1.38E-02 
HH12 NDUFA5 NADH:ubiquinone oxidoreductase subunit A5 0.80 6.00E-04 1.38E-02 
HH12 SPP1 secreted phosphoprotein 1 -0.90 6.00E-04 1.38E-02 
HH12 VAV2 vav 2 guanine nucleotide exchange factor -0.87 6.00E-04 1.38E-02 
HH12 CDH11 cadherin 11, type 2, OB-cadherin (osteoblast) -0.73 6.50E-04 1.43E-02 
HH12 CNOT4 CCR4-NOT transcription complex subunit 4 -0.91 6.50E-04 1.43E-02 
HH12 DPF2 D4, zinc and double PHD fingers family 2 -0.88 6.50E-04 1.43E-02 
HH12 GLG1 golgi glycoprotein 1 -0.74 6.50E-04 1.43E-02 





HH12 MYEOV2 COP9 signalosome subunit 9 0.81 6.50E-04 1.43E-02 
HH12 NFASC neurofascin -0.93 6.50E-04 1.43E-02 
HH12 ODF2 outer dense fiber of sperm tails 2 -0.72 6.50E-04 1.43E-02 
HH12 RPL17 ribosomal protein L17 1.07 6.50E-04 1.43E-02 
HH12 RRAD Ras-related associated with diabetes 1.19 6.50E-04 1.43E-02 
HH12 ELL elongation factor RNA polymerase II -0.80 7.00E-04 1.50E-02 
HH12 GEM GTP binding protein overexpressed in skeletal muscle -2.66 7.00E-04 1.50E-02 
HH12 NRK Nik related kinase -1.07 7.00E-04 1.50E-02 
HH12 RPL34 ribosomal protein L34 0.82 7.00E-04 1.50E-02 
HH12 STAT3 
signal transducer and activator of transcription 3 (acute-
phase response factor) 
-0.80 7.00E-04 1.50E-02 
HH12 YRK proto-oncogene tyrosine-protein kinase Yrk -1.14 7.00E-04 1.50E-02 
HH12 NAB1 NGFI-A binding protein 1 (EGR1 binding protein 1) -1.06 7.50E-04 1.60E-02 
HH12 NDUFB5 NADH:ubiquinone oxidoreductase subunit B5 0.78 7.50E-04 1.60E-02 
HH12 CECR2 cat eye syndrome chromosome region, candidate 2 -0.84 8.00E-04 1.67E-02 
HH12 GAP43 growth associated protein 43 -0.95 8.00E-04 1.67E-02 
HH12 RBMS1 RNA binding motif single stranded interacting protein 1 -0.77 8.00E-04 1.67E-02 
HH12 RGMA RGM domain family, member A -1.03 8.00E-04 1.67E-02 
HH12 TMLHE trimethyllysine hydroxylase, epsilon -0.72 8.00E-04 1.67E-02 
HH12 ASNS asparagine synthetase (glutamine-hydrolyzing) 0.75 8.50E-04 1.74E-02 
HH12 CALD1 caldesmon 1 -0.76 8.50E-04 1.74E-02 
HH12 GNOT1 Gnot1 homeodomain protein -1.74 8.50E-04 1.74E-02 
HH12 PCDH1 protocadherin 1 -0.90 8.50E-04 1.74E-02 
HH12 SUB1 SUB1 homolog (S. cerevisiae) 0.80 8.50E-04 1.74E-02 
HH12 ADCK3 aarF domain containing kinase 3 -0.74 9.00E-04 1.81E-02 





HH12 BMPER BMP binding endothelial regulator -1.51 9.00E-04 1.81E-02 
HH12 C26H6ORF125 chromosome 26 open reading frame, human C6orf125 0.77 9.00E-04 1.81E-02 
HH12 REEP5 receptor accessory protein 5 0.83 9.00E-04 1.81E-02 
HH12 RPRD2 regulation of nuclear pre-mRNA domain containing 2 -0.76 9.00E-04 1.81E-02 
HH12 APBB1IP 
amyloid beta (A4) precursor protein-binding, family B, 
member 1 interacting protein 
-1.20 9.50E-04 1.88E-02 
HH12 LSM8 
LSM8 homolog, U6 small nuclear RNA associated (S. 
cerevisiae) 
0.83 9.50E-04 1.88E-02 
HH12 MRPS25 mitochondrial ribosomal protein S25 0.72 9.50E-04 1.88E-02 
HH12 DIO3 deiodinase, iodothyronine, type III 0.97 1.00E-03 1.96E-02 
HH12 TCF7 transcription factor 7 (T-cell specific, HMG-box) -1.86 1.00E-03 1.96E-02 
HH12 ZNF609 zinc finger protein 609 -0.77 1.00E-03 1.96E-02 
HH12 CST3 cystatin C 0.70 1.05E-03 2.02E-02 
HH12 HAND1 heart and neural crest derivatives expressed 1 -0.80 1.05E-03 2.02E-02 
HH12 LDB3 LIM domain binding 3 1.17 1.05E-03 2.02E-02 
HH12 LSAMP limbic system-associated membrane protein -1.25 1.05E-03 2.02E-02 
HH12 STK40 serine/threonine kinase 40 -0.73 1.05E-03 2.02E-02 
HH12 ACTA1 actin, alpha 1, skeletal muscle 0.87 1.10E-03 2.08E-02 
HH12 COL4A2 collagen, type IV, alpha 2 -0.76 1.10E-03 2.08E-02 
HH12 SMPX small muscle protein, X-linked 1.13 1.10E-03 2.08E-02 
HH12 TMEM121 transmembrane protein 121 0.74 1.10E-03 2.08E-02 
HH12 ACACA acetyl-CoA carboxylase alpha -0.74 1.15E-03 2.14E-02 
HH12 COL4A1 collagen, type IV, alpha 1 -0.74 1.15E-03 2.14E-02 
HH12 ELF1 E74-like factor 1 (ets domain transcription factor) -1.02 1.15E-03 2.14E-02 
HH12 MRPL48 mitochondrial ribosomal protein L48 0.73 1.15E-03 2.14E-02 
HH12 NBL1 neuroblastoma, suppression of tumorigenicity 1 -0.83 1.15E-03 2.14E-02 





HH12 ACTN2 actinin, alpha 2 0.85 1.20E-03 2.19E-02 
HH12 CCDC50 coiled-coil domain containing 50 -0.79 1.20E-03 2.19E-02 
HH12 HDLBP high density lipoprotein binding protein -0.85 1.20E-03 2.19E-02 
HH12 MYH10 myosin, heavy chain 10, non-muscle -0.80 1.20E-03 2.19E-02 
HH12 TGM4 transglutaminase 4 (prostate) -2.26 1.20E-03 2.19E-02 
HH12 TMEM60 transmembrane protein 60 0.92 1.20E-03 2.19E-02 
HH12 SLC30A5 solute carrier family 30 (zinc transporter), member 5 0.73 1.25E-03 2.26E-02 
HH12 TMEM258 transmembrane protein 258 0.74 1.25E-03 2.26E-02 
HH12 FMO6P Flavin Containing Monooxygenase 6 Pseudogene -1.70 1.35E-03 2.40E-02 
HH12 HAT1 histone acetyltransferase 1 0.72 1.35E-03 2.40E-02 
HH12 LMO2 LIM domain only 2 (rhombotin-like 1) -0.73 1.35E-03 2.40E-02 
HH12 SRGAP3 SLIT-ROBO Rho GTPase activating protein 3 -0.90 1.35E-03 2.40E-02 
HH12 TSPAN18 tetraspanin 18 -1.39 1.35E-03 2.40E-02 
HH12 C1H7orf73 chromosome 7 open reading frame 73 0.75 1.40E-03 2.47E-02 
HH12 EMC2 ER membrane protein complex subunit 2 0.72 1.40E-03 2.47E-02 
HH12 APOD apolipoprotein D -2.08 1.45E-03 2.52E-02 
HH12 LDB1 LIM domain binding 1 -0.84 1.45E-03 2.52E-02 
HH12 MEIS1 Meis homeobox 1 -0.72 1.45E-03 2.52E-02 
HH12 N6AMT1 N-6 adenine-specific DNA methyltransferase 1 (putative) 0.73 1.45E-03 2.52E-02 
HH12 C10H15orf61 
chromosome 26 open reading frame, human 
C6orf125(C26H6ORF125) 
0.85 1.50E-03 2.56E-02 
HH12 FOXL2 forkhead box L2 -2.38 1.50E-03 2.56E-02 
HH12 ITIH2 inter-alpha-trypsin inhibitor heavy chain 2 -1.84 1.50E-03 2.56E-02 
HH12 PCDH19 protocadherin 19 -1.01 1.50E-03 2.56E-02 
HH12 POLR3H polymerase (RNA) III subunit H 0.72 1.50E-03 2.56E-02 





HH12 SDC3 syndecan 3 -1.20 1.50E-03 2.56E-02 
HH12 MYO1A myosin IA -0.95 1.55E-03 2.64E-02 
HH12 COL22A1 collagen, type XXII, alpha 1 -0.97 1.60E-03 2.71E-02 
HH12 LHX1 LIM homeobox 1 -3.01 1.65E-03 2.76E-02 
HH12 MSRB3 methionine sulfoxide reductase B3 0.96 1.65E-03 2.76E-02 
HH12 NKX3-2 NK3 homeobox 2 -0.82 1.65E-03 2.76E-02 
HH12 XIRP1 xin actin-binding repeat containing 1 0.79 1.65E-03 2.76E-02 
HH12 AP3S2 adaptor related protein complex 3 sigma 2 subunit 0.74 1.70E-03 2.79E-02 
HH12 APCDD1 adenomatosis polyposis coli down-regulated 1 -0.72 1.70E-03 2.79E-02 
HH12 GATAD2A GATA zinc finger domain containing 2A -0.68 1.70E-03 2.79E-02 
HH12 PITX2 paired-like homeodomain 2 -0.69 1.70E-03 2.79E-02 
HH12 PTCHD2 dispatched RND transporter family member 3 -1.15 1.70E-03 2.79E-02 
HH12 UQCRFS1 
ubiquinol-cytochrome c reductase, Rieske iron-sulfur 
polypeptide 1 
0.69 1.70E-03 2.79E-02 
HH12 ATP6V1G1 ATPase, H+ transporting, lysosomal 13kDa, V1 subunit G1 0.69 1.75E-03 2.81E-02 
HH12 C12ORF57 chromosome 1 open reading frame, human C12orf57 0.74 1.75E-03 2.81E-02 
HH12 CFC1B cripto, FRL-1, cryptic family 1B 0.76 1.75E-03 2.81E-02 
HH12 DNAJC12 DnaJ heat shock protein family (Hsp40) member C12 0.95 1.75E-03 2.81E-02 
HH12 NDUFA4 
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 
4, 9kDa 
0.73 1.75E-03 2.81E-02 
HH12 RGS6 regulator of G-protein signaling 6 0.99 1.75E-03 2.81E-02 
HH12 WDR44 WD repeat domain 44 -0.72 1.75E-03 2.81E-02 
HH12 ISL1 ISL LIM homeobox 1 0.99 1.80E-03 2.86E-02 
HH12 KANK1 KN motif and ankyrin repeat domains 1 -0.72 1.80E-03 2.86E-02 
HH12 ZNF692 zinc finger protein 692 -0.78 1.80E-03 2.86E-02 





HH12 ABRACL ABRA C-terminal like 0.79 1.90E-03 2.99E-02 
HH12 GTF2A2 general transcription factor IIA 2 0.71 1.90E-03 2.99E-02 
HH12 MAT1A methionine adenosyltransferase I, alpha 1.41 1.90E-03 2.99E-02 
HH12 RBPMS2 RNA binding protein with multiple splicing 2 0.69 1.95E-03 3.06E-02 
HH12 CSNK1E casein kinase 1, epsilon -0.71 2.00E-03 3.10E-02 
HH12 PIGBOS1 PIGB opposite strand 1 0.85 2.00E-03 3.10E-02 
HH12 PPIH peptidylprolyl isomerase H 0.69 2.00E-03 3.10E-02 
HH12 WDR61 WD repeat domain 61 0.70 2.00E-03 3.10E-02 
HH12 RPL27A ribosomal protein L27a 0.83 2.05E-03 3.17E-02 
HH12 CCDC58 coiled-coil domain containing 58 0.73 2.10E-03 3.22E-02 
HH12 DTYMK deoxythymidylate kinase 0.69 2.10E-03 3.22E-02 
HH12 SHFM1 split hand/foot malformation (ectrodactyly) type 1 0.86 2.10E-03 3.22E-02 
HH12 ARHGEF6 Rac/Cdc42 guanine nucleotide exchange factor (GEF) 6 -0.95 2.15E-03 3.26E-02 
HH12 COMMD4 COMM domain containing 4 0.74 2.15E-03 3.26E-02 
HH12 MRPL21 mitochondrial ribosomal protein L21 0.70 2.15E-03 3.26E-02 
HH12 TUBB tubulin, beta class I -0.90 2.15E-03 3.26E-02 
HH12 HPGDS hematopoietic prostaglandin D synthase 2.06 2.20E-03 3.30E-02 
HH12 RBM38 RNA binding motif protein 38 0.68 2.20E-03 3.30E-02 
HH12 VGLL2 vestigial like family member 2 1.47 2.20E-03 3.30E-02 
HH12 VMA21 VMA21 vacuolar H+-ATPase homolog (S. cerevisiae) 0.74 2.25E-03 3.37E-02 
HH12 CXCR7 chemokine (C-X-C motif) receptor 7 0.71 2.30E-03 3.42E-02 
HH12 MRPS35 mitochondrial ribosomal protein S35 0.67 2.30E-03 3.42E-02 
HH12 AP3S1 adaptor-related protein complex 3, sigma 1 subunit 0.72 2.35E-03 3.48E-02 
HH12 CHRM4 cholinergic receptor, muscarinic 4 -1.10 2.35E-03 3.48E-02 
HH12 LYRM2 LYR motif containing 2 0.92 2.40E-03 3.53E-02 
HH12 RPL37 ribosomal protein L37 0.74 2.40E-03 3.53E-02 





HH12 EDEM1 ER degradation enhancer, mannosidase alpha-like 1 -0.86 2.45E-03 3.58E-02 
HH12 NDUFA8 NADH:ubiquinone oxidoreductase subunit A8 0.68 2.45E-03 3.58E-02 
HH12 LGI2 leucine-rich repeat LGI family, member 2 0.97 2.50E-03 3.65E-02 
HH12 PAX6 paired box 6 -0.81 2.55E-03 3.70E-02 
HH12 RIOK2 RIO kinase 2 0.68 2.55E-03 3.70E-02 
HH12 GSTO1 glutathione S-transferase omega 1 0.68 2.60E-03 3.75E-02 
HH12 ITPKA inositol-trisphosphate 3-kinase A -0.94 2.60E-03 3.75E-02 
HH12 CRTAP cartilage associated protein 0.75 2.65E-03 3.79E-02 
HH12 DPYSL3 dihydropyrimidinase-like 3 -0.66 2.65E-03 3.79E-02 
HH12 SPECC1L 
sperm antigen with calponin homology and coiled-coil 
domains 1-like 
-0.72 2.65E-03 3.79E-02 
HH12 PTTG1 pituitary tumor-transforming 1 0.70 2.70E-03 3.84E-02 
HH12 SEMA3D 
sema domain, immunoglobulin domain (Ig), short basic 
domain, secreted, (semaphorin) 3D 
-0.74 2.70E-03 3.84E-02 
HH12 ALDH1A2 aldehyde dehydrogenase 1 family, member A2 -0.70 2.75E-03 3.86E-02 
HH12 DENR density-regulated protein 0.68 2.75E-03 3.86E-02 
HH12 NTPCR nucleoside-triphosphatase, cancer-related 0.77 2.75E-03 3.86E-02 
HH12 PNRC1 proline rich nuclear receptor coactivator 1 -0.67 2.75E-03 3.86E-02 
HH12 STXBP1 syntaxin binding protein 1 -0.86 2.75E-03 3.86E-02 
HH12 IMMP1L inner mitochondrial membrane peptidase subunit 1 0.95 2.80E-03 3.92E-02 
HH12 TLN1 talin 1 -0.67 2.85E-03 3.98E-02 
HH12 ENY2 enhancer of yellow 2 homolog (Drosophila) 0.69 2.90E-03 4.01E-02 
HH12 GRB2 growth factor receptor bound protein 2 -0.74 2.90E-03 4.01E-02 
HH12 MYOM1 myomesin 1 0.72 2.90E-03 4.01E-02 
HH12 CHST6 
carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 
6 
0.68 2.95E-03 4.06E-02 





HH12 IL17D interleukin 17D down 2.95E-03 4.06E-02 
HH12 PXN paxillin -0.75 3.15E-03 4.32E-02 
HH12 FURIN furin (paired basic amino acid cleaving enzyme) -0.79 3.20E-03 4.35E-02 
HH12 PBRM1 polybromo 1 -0.65 3.20E-03 4.35E-02 
HH12 TCEB1 transcription elongation factor B subunit 1 0.67 3.20E-03 4.35E-02 
HH12 WNT3A wingless-type MMTV integration site family, member 3A -1.49 3.20E-03 4.35E-02 
HH12 NELL2 NEL-like 2 -0.72 3.25E-03 4.40E-02 
HH12 CASQ2 calsequestrin 2 (cardiac muscle) 0.98 3.30E-03 4.42E-02 
HH12 PSMA2 Uncharacterized protein 0.66 3.30E-03 4.42E-02 
HH12 RPS6 ribosomal protein S6 1.13 3.30E-03 4.42E-02 
HH12 SIK1 salt-inducible kinase 1 0.69 3.30E-03 4.42E-02 
HH12 UQCR10 ubiquinol-cytochrome c reductase, complex III subunit X 0.71 3.35E-03 4.47E-02 
HH12 VEZF1 vascular endothelial zinc finger 1 -0.72 3.35E-03 4.47E-02 
HH12 DPY30 
dpy-30, histone methyltransferase complex regulatory 
subunit 
0.68 3.40E-03 4.48E-02 
HH12 EDNRB endothelin receptor type B -0.95 3.40E-03 4.48E-02 
HH12 PGC progastricsin 1.01 3.40E-03 4.48E-02 
HH12 POLR2F polymerase (RNA) II subunit F 0.67 3.40E-03 4.48E-02 
HH12 RPL37A ribosomal protein L37a 0.71 3.40E-03 4.48E-02 
HH12 YAP1 Yes-associated protein 1 -0.70 3.45E-03 4.53E-02 
HH12 NF2 neurofibromin 2 (bilateral acoustic neuroma) -0.66 3.50E-03 4.56E-02 
HH12 PODXL podocalyxin-like -0.68 3.50E-03 4.56E-02 
HH12 WDR36 WD repeat domain 36 0.65 3.50E-03 4.56E-02 
HH12 AGTPBP1 ATP/GTP binding protein 1 1.23 3.55E-03 4.59E-02 
HH12 FGF19 fibroblast growth factor 19 0.89 3.55E-03 4.59E-02 





HH12 TOP2A topoisomerase (DNA) II alpha 170kDa -0.68 3.55E-03 4.59E-02 
HH12 RBP5 retinol binding protein 5, cellular 0.65 3.60E-03 4.64E-02 
HH12 HDAC7 histone deacetylase 7 -0.67 3.65E-03 4.70E-02 
HH12 LRP1 low density lipoprotein receptor-related protein 1 -0.69 3.70E-03 4.74E-02 
HH12 TNNI3K TNNI3 interacting kinase 1.94 3.70E-03 4.74E-02 
HH12 COLEC10 collectin sub-family member 10 (C-type lectin) -1.61 3.75E-03 4.78E-02 
HH12 GHRL ghrelin/obestatin prepropeptide 2.00 3.75E-03 4.78E-02 
HH12 GNAI2 
guanine nucleotide binding protein (G protein), alpha 
inhibiting activity polypeptide 2 
-0.66 3.80E-03 4.82E-02 
HH12 VIT vitrin -1.07 3.80E-03 4.82E-02 
HH12 RAD54L2 RAD54-like 2 -0.65 3.85E-03 4.87E-02 
HH12 DYRK1A 
dual-specificity tyrosine-(Y)-phosphorylation regulated 
kinase 1A 
-0.83 3.90E-03 4.91E-02 
HH12 PMEL premelanosome protein -0.81 3.90E-03 4.91E-02 
HH12 MELK maternal embryonic leucine zipper kinase 0.66 3.95E-03 4.96E-02 
HH12 HMHA1 histocompatibility (minor) HA-1 -0.96 4.00E-03 4.99E-02 
HH12 TP53I11 tumor protein p53 inducible protein 11 -0.73 4.00E-03 4.99E-02 
HH12 YES1 v-yes-1 Yamaguchi sarcoma viral oncogene homolog 1 -0.72 4.00E-03 4.99E-02 
HH14 MARC2 Mitochondrial Amidoxime Reducing Component 2 -0.53 8.20E-03 9.67E-02 
HH14 ACTN4 actinin, alpha 4 0.39 4.53E-02 3.25E-01 
HH14 AKR1B10 
aldo-keto reductase family 1, member B10 (aldose 
reductase) 
-1.59 4.15E-03 5.72E-02 
HH14 AKR1B1L 
aldo-keto reductase family 1, member B1-like (aldose 
reductase) 
-0.58 1.71E-02 1.67E-01 
HH14 ALDH1A2 aldehyde dehydrogenase 1 family, member A2 -0.56 7.10E-03 8.75E-02 
HH14 ANGPTL2 angiopoietin-like 2 -0.51 2.87E-02 2.41E-01 
HH14 AQP1 aquaporin 1 1.23 2.00E-04 4.37E-03 





HH14 BFSP2 beaded filament structural protein 2 -0.74 5.00E-02 3.46E-01 
HH14 C9H21ORF2 
chromosome 9 open reading frame, human 
C21orf2(C9H21ORF2) 
-0.47 2.80E-02 2.37E-01 
HH14 CACNG3 calcium channel, voltage-dependent, gamma subunit 3 -0.68 4.14E-02 3.09E-01 
HH14 CAPN2 calpain 2, (m/II) large subunit -0.54 3.25E-02 2.62E-01 
HH14 CD44 CD44 molecule (Indian blood group) -1.27 2.80E-02 2.37E-01 
HH14 CDX1 caudal type homeobox 1 1.42 2.01E-02 1.88E-01 
HH14 CENPF centromere protein F -0.42 3.11E-02 2.55E-01 
HH14 CETN2 centrin, EF-hand protein, 2 -0.47 1.81E-02 1.74E-01 
HH14 COL2A1 collagen, type II, alpha 1 0.63 1.60E-03 2.61E-02 
HH14 CPPED1 calcineurin-like phosphoesterase domain containing 1 -0.49 3.18E-02 2.58E-01 
HH14 CRABP1 cellular retinoic acid binding protein 1 -0.41 3.55E-02 2.78E-01 
HH14 CRYGS crystallin, gamma S up 1.50E-04 3.38E-03 
HH14 CXCL14 C-X-C motif chemokine ligand 14 -0.41 3.92E-02 2.98E-01 
HH14 DENR density-regulated protein -0.39 4.65E-02 3.30E-01 
HH14 ENPP4 
ectonucleotide pyrophosphatase/phosphodiesterase 4 
(putative) 
-0.55 4.42E-02 3.20E-01 
HH14 ERNI early response to neural induction ERNI -1.22 1.75E-02 1.70E-01 
HH14 FABP3 
fatty acid binding protein 3, muscle and heart (mammary-
derived growth inhibitor) 
-0.61 2.01E-02 1.87E-01 
HH14 FAM133B family with sequence similarity 133, member B -0.46 1.89E-02 1.79E-01 
HH14 FGA fibrinogen alpha chain -1.07 1.40E-03 2.32E-02 
HH14 FGB fibrinogen beta chain -0.60 1.39E-02 1.43E-01 
HH14 FGG fibrinogen gamma chain -0.61 1.90E-02 1.80E-01 
HH14 FST follistatin 0.51 2.28E-02 2.06E-01 
HH14 G0S2 G0/G1 switch 2 -1.33 3.08E-02 2.53E-01 





HH14 GBP guanylate binding protein -1.57 4.55E-02 3.26E-01 
HH14 GLI1 GLI family zinc finger 1 0.48 2.75E-02 2.34E-01 
HH14 GUCA2B guanylate cyclase activator 2B (uroguanylin) 5.27 5.00E-05 1.23E-03 
HH14 HAND1 heart and neural crest derivatives expressed 1 0.53 2.46E-02 2.17E-01 
HH14 HGF hepatocyte growth factor -0.93 2.05E-02 1.90E-01 
HH14 HK2 hexokinase 2 0.44 2.67E-02 2.29E-01 
HH14 HMGN3 high mobility group nucleosomal binding domain 3 -0.40 4.23E-02 3.13E-01 
HH14 HNRPK heterogeneous nuclear ribonucleoprotein K -0.62 1.40E-02 1.44E-01 
HH14 IFT52 intraflagellar transport 52 -0.48 2.45E-02 2.16E-01 
HH14 JUN jun proto-oncogene -0.56 5.35E-03 7.01E-02 
HH14 KHDRBS1 
KH domain containing, RNA binding, signal transduction 
associated 1 
-0.45 2.16E-02 1.98E-01 
HH14 LAMB2 laminin, beta 2 (laminin S) 0.60 3.90E-02 2.97E-01 
HH14 LOC425137 
aldo-keto reductase family 1, member B1-
like(LOC425137) 
-0.75 1.46E-02 1.49E-01 
HH14 LOC427025 Nipped-B homolog-like(LOC427025) -0.57 2.83E-02 2.39E-01 
HH14 LSP1 lymphocyte-specific protein 1 -0.41 3.98E-02 3.01E-01 
HH14 MAP6 microtubule associated protein 6 -0.46 4.37E-02 3.19E-01 
HH14 MEOX1 mesenchyme homeobox 1 -0.45 2.36E-02 2.10E-01 
HH14 MFI2 melanotransferrin 0.68 3.96E-02 3.00E-01 
HH14 MIR1306 microRNA 1306 down 7.40E-03 8.90E-02 
HH14 MIR130B microRNA 130b up 2.32E-02 2.08E-01 
HH14 MIR135A1 microRNA 135a-1 up 1.80E-02 1.73E-01 
HH14 MIR1454 microRNA 1454 up 4.67E-02 3.31E-01 
HH14 MIR1562 microRNA 1562 down 7.40E-03 8.90E-02 
HH14 MIR1564 microRNA 1564 up 2.32E-02 2.08E-01 
HH14 MIR1612 microRNA 1612 down 7.40E-03 8.90E-02 





HH14 MIR1615 microRNA 1615 up 2.32E-02 2.08E-01 
HH14 MIR1653 microRNA 1653 up 1.06E-02 1.17E-01 
HH14 MIR1683 microRNA 1683 up 1.06E-02 1.17E-01 
HH14 MIR1689 microRNA 1689 up 4.40E-02 3.20E-01 
HH14 MIR1747 microRNA 1747 down 7.40E-03 8.90E-02 
HH14 MIR1773 microRNA 1773 down 7.40E-03 8.90E-02 
HH14 MIR1774 microRNA 1774 up 4.40E-02 3.20E-01 
HH14 MIR1778 microRNA 1778 down 7.40E-03 8.90E-02 
HH14 MIR1787 microRNA 1787 up 2.32E-02 2.08E-01 
HH14 MIR216B microRNA 216b up 3.12E-02 2.56E-01 
HH14 MIR3607 microRNA 3607 up 4.40E-02 3.20E-01 
HH14 MIR454 microRNA 454 up 2.32E-02 2.08E-01 
HH14 MIR6569 microRNA 6569 down 7.40E-03 8.90E-02 
HH14 MIR6580 microRNA 6580 down 7.40E-03 8.90E-02 
HH14 MIR6592 microRNA 6592 up 4.40E-02 3.20E-01 
HH14 MIR6602 microRNA 6602 up 1.80E-02 1.73E-01 
HH14 MIR6618 microRNA 6618 up 4.40E-02 3.20E-01 
HH14 MIR6640 microRNA 6640 down 7.40E-03 8.90E-02 
HH14 MIR6700 microRNA 6700 up 4.40E-02 3.20E-01 
HH14 MIR7-1 microRNA 7-1 up 2.32E-02 2.08E-01 
HH14 MIR762 microRNA 762 down 7.40E-03 8.90E-02 
HH14 MTERFD1 mitochondrial transcription termination factor 3 -0.45 2.33E-02 2.09E-01 
HH14 MXD4 MAX dimerization protein 4 -0.61 4.03E-02 3.03E-01 
HH14 MYOM2 myomesin 2 0.60 6.15E-03 7.82E-02 
HH14 OVAL ovalbumin (SERPINB14) -1.95 4.80E-03 6.40E-02 
HH14 PDLIM3 PDZ and LIM domain 3 0.97 3.42E-02 2.71E-01 
HH14 PEX2 peroxisomal biogenesis factor 2 -0.51 1.61E-02 1.60E-01 





HH14 PKIB protein kinase (cAMP-dependent, catalytic) inhibitor beta -0.97 4.29E-02 3.15E-01 
HH14 PLCXD1 
phosphatidylinositol-specific phospholipase C, X domain 
containing 1 
1.39 1.70E-03 2.73E-02 
HH14 PMEL premelanosome protein 0.84 1.52E-02 1.53E-01 
HH14 PRKDC protein kinase, DNA-activated, catalytic polypeptide -0.51 2.57E-02 2.23E-01 
HH14 PSMB1 proteasome subunit beta 1 -0.40 4.62E-02 3.29E-01 
HH14 PSMB5 proteasome subunit beta 5 0.84 1.19E-02 1.27E-01 
HH14 PTCH1 patched 1 0.47 2.32E-02 2.08E-01 
HH14 PTGR2 prostaglandin reductase 2 -0.54 1.23E-02 1.30E-01 
HH14 RAD9A RAD9 checkpoint clamp component A 0.48 4.87E-02 3.40E-01 
HH14 RBP riboflavin binding protein 1.23 4.09E-02 3.05E-01 
HH14 RBP4 retinol binding protein 4 2.49 5.00E-05 1.23E-03 
HH14 RDM1 RAD52 motif containing 1 -0.55 1.97E-02 1.85E-01 
HH14 RPAP3 RNA polymerase II associated protein 3 -0.40 4.65E-02 3.30E-01 
HH14 RPL32 ribosomal protein L32 -0.41 3.98E-02 3.01E-01 
HH14 SELM selenoprotein M -0.44 3.57E-02 2.80E-01 
HH14 SEPP1 selenoprotein P, plasma, 1 -0.45 4.08E-02 3.05E-01 
HH14 SLC4A1 solute carrier family 4, anion exchanger, member 1 0.58 3.60E-02 2.82E-01 
HH14 SLC7A9 
solute carrier family 7 (amino acid transporter light chain, 
bo,+ system), member 9 
2.39 4.50E-04 8.97E-03 
HH14 SNRPA1 small nuclear ribonucleoprotein polypeptide A' -0.44 2.76E-02 2.34E-01 
HH14 SULT1C3 sulfotransferase family, cytosolic, 1C, member 3 1.62 7.00E-03 8.66E-02 
HH14 THG1L tRNA-histidine guanylyltransferase 1 like -0.45 2.65E-02 2.28E-01 
HH14 THYN1 thymocyte nuclear protein 1 -0.42 4.05E-02 3.04E-01 
HH14 TIMM10 
translocase of inner mitochondrial membrane 10 
homolog (yeast) 
-0.48 3.78E-02 2.91E-01 





HH14 TTR transthyretin 1.21 5.00E-05 1.23E-03 
HH14 UBAP2 ubiquitin associated protein 2 -0.68 1.03E-02 1.14E-01 
HH14 UCHL5 ubiquitin C-terminal hydrolase L5 -0.38 4.89E-02 3.41E-01 
HH14 UFSP2 UFM1-specific peptidase 2 -0.62 3.70E-03 5.20E-02 
HH14 VIPR2 vasoactive intestinal peptide receptor 2 1.99 1.35E-03 2.26E-02 
HH14 WT1 Wilms tumor protein homolog -0.93 1.02E-02 1.13E-01 
      
Supplemental Table 1.  DEG HH10, 12, and 14. 
Complete list of all significant genes from RNA-Seq for all three stages, HH10, 12, and 14. 






Enriched Gene Ontology Terms for HH 10-12-14 
Stage DAVID Enriched Go Terms Genes P-Value 
HH10 DNA-templated transcription 11 2.55E-03 
HH10 Multicellular organism development 7 4.65E-03 
HH10 Negative regulation of neuron differentiation 6 1.22E-05 
HH10 Ventricular cardiac muscle tissue morphogenesis 5 1.74E-06 
HH10 Protein stabilization 4 2.01E-02 
HH10 Axon guidance 4 2.17E-02 
HH10 Regulation of muscle contraction 3 7.49E-04 
HH10 Positive regulation of ATPase activity 3 3.98E-03 
HH10 
Signal transduction involved in regulation of gene 
expression 3 4.75E-03 
HH10 Cardiac muscle contraction 3 7.43E-03 
HH10 Stem cell differentiation 3 8.44E-03 
HH10 Platelet aggregation 3 1.71E-02 
HH10 Protein complex assembly 3 1.86E-02 
HH10 Response to virus 3 2.83E-02 
HH10 Activation of meiosis 2 1.75E-02 
HH10 Positive regulation of mesenchymal cell apoptotic process 2 1.75E-02 
HH10 BMP signaling pathway involved in heart development 2 1.75E-02 
HH10 Protein localization to juxtaparanode region of axon 2 2.61E-02 
HH10 Lipoprotein biosynthetic process 2 2.61E-02 
HH10 Thyroid hormone transport 2 2.61E-02 
HH10 Embryonic nail plate morphogenesis 2 2.61E-02 
HH10 Cartilage morphogenesis 2 3.47E-02 
HH10 Positive regulation of protein processing 2 4.32E-02 
HH10 Forebrain dorsal/ventral pattern formation 2 4.32E-02 
HH10 
Negative regulation of transcription regulatory region 
DNA binding 2 4.32E-02 
HH10 Triglyceride catabolic process 2* 8.45E-02 
HH10 Ion transport 2* 9.25E-02 
HH10 Iron ion homeostasis 2* 9.25E-02 
HH12 DNA-templated transcription 36 4.15E-07 
HH12 DNA-templated regulation of transcription 31 1.29E-05 
HH12 
Positive regulation of transcription from RNA polymerase 
II promoter 29 2.62E-04 
HH12 Cell differentiation 20 5.89E-07 





HH12 Multicellular organism development 17 4.64E-04 
HH12 
Negative regulation of transcription from RNA polymerase 
II promoter 16 4.98E-02 
HH12 
Regulation of transcription from RNA polymerase II 
promoter 14 1.24E-02 
HH12 Axon guidance 13 3.23E-06 
HH12 Heart development 12 5.72E-04 
HH12 Negative regulation of cell proliferation 12 1.55E-02 
HH12 Transcription from RNA polymerase II promoter 11 1.66E-03 
HH12 Cell adhesion 11 1.44E-02 
HH12 Negative regulation of apoptotic process 11 5.43E-02 
HH12 Positive regulation of cell proliferation 10 9.13E-02 
HH12 Angiogenesis 9 1.46E-02 
HH12 Positive regulation of cell migration 8 5.43E-02 
HH12 Positive regulation of defense response to virus by host 7 1.07E-02 
HH12 Ventricular cardiac muscle tissue morphogenesis 6 1.92E-05 
HH12 Regulation of heart rate 6 3.20E-05 
HH12 Cardiac muscle contraction 6 1.11E-04 
HH12 Muscle contraction 6 7.99E-04 
HH12 Platelet aggregation 6 9.92E-04 
HH12 Heart looping 6 6.00E-03 
HH12 Regulation of cell migration 6 8.64E-03 
HH12 Neural crest cell migration 6 1.61E-02 
HH12 Positive regulation of angiogenesis 6 2.49E-02 
HH12 Negative regulation of cell migration 6 2.70E-02 
HH12 Anterior/posterior pattern specification 6 4.45E-02 
HH12 Brain development 6 6.04E-02 
HH12 Wnt signaling pathway 6 6.39E-02 
HH12 Negative regulation of neuron apoptotic process 6 7.13E-02 
HH12 Pituitary gland development 5 2.99E-03 
HH12 Positive regulation of cell adhesion 5 3.69E-03 
HH12 Cellular response to retinoic acid 5 7.55E-03 
HH12 Ephrin receptor signaling pathway 5 8.81E-03 
HH12 Vasculogenesis 5 2.40E-02 
HH12 Positive regulation of neuron differentiation 5 3.23E-02 
HH12 Lung development 5 4.20E-02 
HH12 Xenophagy 5 9.52E-02 
HH12 Cardiac myofibril assembly 4 1.32E-03 
HH12 Negative regulation of cell-cell adhesion 4 3.00E-03 





HH12 Hydrogen ion transmembrane transport 4 4.18E-03 
HH12 Morphogenesis of an epithelium 4 5.59E-03 
HH12 Artery morphogenesis 4 5.59E-03 
HH12 
Signal transduction involved in regulation of gene 
expression 4 7.27E-03 
HH12 Anterior/posterior axis specification 4 9.21E-03 
HH12 Heart morphogenesis 4 1.39E-02 
HH12 Bone morphogenesis 4 1.39E-02 
HH12 Cellular protein localization 4 3.07E-02 
HH12 Embryonic forelimb morphogenesis 4 3.49E-02 
HH12 Embryonic hindlimb morphogenesis 4 3.94E-02 
HH12 Skeletal muscle tissue development 4 4.42E-02 
HH12 Patterning of blood vessels 4 4.42E-02 
HH12 Protein complex assembly 4 4.92E-02 
HH12 Forebrain development 4 5.46E-02 
HH12 Retina development in camera-type eye 4 6.60E-02 
HH12 Organ morphogenesis 4 8.50E-02 
HH12 Actin filament organization 4 9.88E-02 
HH12 
Regulation of cardiac muscle contraction by regulation of 
the release of sequestered calcium ion 3 3.54E-03 
HH12 Regulation of myotube differentiation 3 3.54E-03 
HH12 Skeletal muscle thin filament assembly 3 6.91E-03 
HH12 Regulation of muscle contraction 3 1.13E-02 
HH12 
Negative regulation of transcription regulatory region 
DNA binding 3 1.13E-02 
HH12 Positive regulation of megakaryocyte differentiation 3 1.65E-02 
HH12 Spinal cord association neuron differentiation 3 1.65E-02 
HH12 Regulation of axon extension 3 1.65E-02 
HH12 Cerebellar Purkinje cell differentiation 3 2.26E-02 
HH12 
Regulation of ventricular cardiac muscle cell membrane 
repolarization 3 2.26E-02 
HH12 Positive regulation of myotube differentiation 3 2.26E-02 
HH12 Endothelial cell activation 3 2.26E-02 
HH12 Intracellular receptor signaling pathway 3 2.94E-02 
HH12 Atrial septum morphogenesis 3 2.94E-02 
HH12 mRNA transcription from RNA polymerase II promoter 3 2.94E-02 
HH12 Hindlimb morphogenesis 3 3.70E-02 
HH12 
Positive regulation of transcription elongation from RNA 
polymerase II promoter 3 3.70E-02 
HH12 Actin filament-based movement 3 4.52E-02 





HH12 Myoblast fusion 3 4.52E-02 
HH12 Respiratory system process 3 4.52E-02 
HH12 Positive regulation of protein tyrosine kinase activity 3* 5.40E-02 
HH12 Embryo development ending in birth or egg hatching 3* 5.40E-02 
HH12 
Anatomical structure formation involved in 
morphogenesis 3* 5.40E-02 
HH12 Embryonic digestive tract morphogenesis 3* 5.40E-02 
HH12 Regulation of protein binding 3* 6.33E-02 
HH12 Embryonic digestive tract development 3* 6.33E-02 
HH12 Cellular response to gamma radiation 3* 6.33E-02 
HH12 Smooth muscle contraction 3* 8.34E-02 
HH12 Gastrulation with mouth forming second 3* 8.34E-02 
HH12 Post-anal tail morphogenesis 3* 8.34E-02 
HH12 Positive regulation of myoblast differentiation 3* 8.34E-02 
HH12 Positive regulation of DNA binding 3* 9.41E-02 
HH12 Activation of meiosis 2* 6.84E-02 
HH12 Cardiac left ventricle formation 2* 6.84E-02 
HH12 Negative regulation of CREB transcription factor activity 2* 6.84E-02 
HH12 Positive regulation of epithelial cell differentiation 2* 6.84E-02 
HH12 Eye photoreceptor cell differentiation 2* 6.84E-02 
HH12 
Negative regulation of low-density lipoprotein particle 
receptor catabolic process 2* 6.84E-02 
HH12 Positive regulation of interleukin-1 beta production 2* 6.84E-02 
HH12 Positive regulation of mesenchymal cell apoptotic process 2* 6.84E-02 
HH12 Extraocular skeletal muscle development 2* 6.84E-02 
HH12 BMP signaling pathway involved in heart development 2* 6.84E-02 
HH12 Detection of muscle stretch 2* 6.84E-02 
HH14 
Negative regulation of extrinsic apoptotic signaling 
pathway via death domain receptors 4 1.10E-04 
HH14 Positive regulation of heterotypic cell-cell adhesion 3 1.20E-04 
HH14 Protein polymerization 3 4.00E-04 
HH14 Plasminogen activation 3 6.00E-04 
HH14 Positive regulation of peptide hormone secretion 3 1.10E-03 
HH14 Fibrinolysis 3 1.80E-03 
HH14 Positive regulation of exocytosis 3 1.80E-03 
HH14 Smoothened signaling pathway 4 2.80E-03 
HH14 Positive regulation of vasoconstriction 3 4.60E-03 
HH14 Negative regulation of endothelial cell apoptotic process 3 5.20E-03 





HH14 Positive regulation of protein secretion 3 5.90E-03 
HH14 Platelet aggregation 3 9.50E-03 
HH14 Response to calcium ion 3 1.00E-02 
HH14 Proteolysis involved in cellular protein catabolic process 3 1.10E-02 
HH14 Negative regulation of epithelial cell proliferation 3 1.50E-02 
HH14 Positive regulation of ERK1 and ERK2 cascade 4 1.70E-02 
HH14 RNA Splicing 3 1.70E-02 
HH14 Induction of bacterial agglutination 2 1.90E-02 
HH14 Blood coagulation, fibrin clot formation 2 1.90E-02 
HH14 Heart looping 3 2.00E-02 
HH14 Transcription from RNA polymerase II promoter 4 2.50E-02 
HH14 Cell-matrix adhesion 3 2.70E-02 
HH14 Retinoic acid receptor signaling pathway 2 3.80E-02 
HH14 Retinol metabolic process 2* 6.30E-02 
HH14 Spinal cord motor neuron differentiation 2* 7.50E-02 
HH14 Heart morphogenesis 2* 9.30E-02 
HH14 
Negative regulation of transcription from RNA polymerase 
II promoter 5* 9.60E-02 
*denotes GO term not significant by p-value 
 
Supplemental Table 2.  Full Gene Ontology HH10, 12, and 14. 
Complete list of all Gene Ontology terms for all three stages, HH10, 12, and 14. 
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